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Abstract 
Fanconi Anemia (FA) is an inherited cancer predisposition syndrome that is characterized 
by a cellular hypersensitivity to DNA interstrand crosslinks (ICLs). To repair these DNA 
lesions, the 21 known FA proteins are thought to act in a linear hierarchy: Following ICL 
detection, an upstream FA core complex activates two central FA pathway members, 
FANCD2 and FANCI, via monoubiquitination. Both activated proteins then bind the ICL 
and recruit downstream FA proteins that repair the ICLs. Importantly, we previously 
found that FANCD2 has an additional independent role during the cellular replication 
stress response: it promotes the homologous recombination (HR) dependent restart of 
hydroxyurea (HU) stalled replication forks in concert with other HR DNA repair proteins 
such as the BLM helicase. In this work, we show that FANCD2 promotes replication fork 
restart in concert with downstream FA pathway proteins but independently of the 
upstream FA core complex and thus, independently of FANCD2 monoubiquitination. To 
further our understanding of how FANCD2 promotes replication fork recovery, we 
performed a search for S-phase specific FANCD2 interactors and we identified a novel 
FANCD2 interacting protein, Alpha Thalassemia Retardation X-linked factor (ATRX). 
ATRX is a subunit of the ATRX/DAXX histone H3 chaperone complex that plays 
several key roles in regulating chromatin structure and was recently identified as a 
replication fork recovery factor. Our new findings demonstrate that ATRX forms a 
constitutive complex with FANCD2 and promotes FANCD2 protein stability. Moreover, 
while ATRX is dispensable for DNA ICL repair, it works in concert with FANCD2 to 
promote HU resistance and the restart of HU-stalled replication forks. Remarkably, the 
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HR-dependent replication fork restart requires the histone H3 chaperone activity of both 
the ATRX/DAXX complex and FANCD2 indicating that histone exchange at stalled 
replication forks is a crucial step in fork restart. Altogether, our results support a novel 
non-linear FA pathway model where individual protein members fulfill distinct cellular 
roles to support genomic stability. We propose that FANCD2- and possibly other FA 
pathway proteins- is involved in the deposition of histone H3 variants in the vicinity of 
HU- stalled replication forks to mediate fork recovery. 
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1.1 Cancer biology and genomic instability 
Cells in the human body grow and divide to form new cells according to the needs 
of the body. As cells age or get damaged, they undergo programmed senescence or death 
and are replaced by newer cells. This process of cell division, aging, death and 
replacement is very tightly regulated and is carried out in an orderly manner by the 
cellular machinery. However, this orderly process can break down in some cells and 
allow them to gain “enabling” traits that let them override the regulatory machinery to 
proliferate uncontrollably. Such abnormal cells with the ability to proliferate indefinitely 
are termed cancer cells (Hanahan and Weinberg, 2000; Kinzler and Vogelstein, 1997; 
Tabassum and Polyak, 2015).  
The foundation of carcinogenesis lies in the alterations of genes that control 
cellular growth, division and death. Hanahan and Weinberg aptly compared 
carcinogenesis to a process analogous to Darwinian evolution, wherein successive 
genetic changes confer some growth advantage, eventually leading to the conversion of a 
normal cell to a cancer cell (Hanahan and Weinberg, 2000). Thus, the generation of 
mutational changes is an early etiology for tumorigenesis. Post tumorigenesis, cancer 
cells have an “unstable” genome that is prone to the accumulation of many genetic 
mutations in a successive manner. In fact, instability of the genome is a defining 
characteristic of all neoplastic cells (Kastan and Bartek, 2004; Negrini et al., 2010; Shen, 
2011). As further discussed by Hanahan and Weinberg in 2011, genomic instability was 
appended to the classic “Hallmarks of Cancer”. Genomic instability is now known to be a 
key “enabling” characteristic that promotes the acquisition of other hallmark cancer cell 
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capabilities, including the ability to survive, proliferate and disseminate (Hanahan and 
Weinberg, 2011). 
The integrity of a cell’s genome is constantly threatened by various kinds of 
endogenous and exogenous DNA damaging sources (Helleday et al., 2014). To 
counteract this, cells employ an intricate network of “genomic caretaker proteins”. This 
network encompasses several DNA damage repair (DDR) pathways that are intertwined 
with the “cell cycle checkpoint” machinery that can halt the cell cycle in the face of DNA 
damage to allow DNA repair prior to the next cell division (Kastan and Bartek, 2004; 
Khanna and Jackson, 2001; Kinzler and Vogelstein, 1997).  
There are three cell cycle checkpoints called G1 phase, S phase and G2/M 
transition ‘checkpoints’. G1 phase checkpoint: This checkpoint is activated in response to 
damaged DNA in G1 phase, and thus, prevents cells from initiating replication. Upon 
checkpoint activation, ATM (Ataxia-Telangiectasia Mutated) and ATR (Ataxia-
Telangiectasia and RAD3 related) kinases mediate the phosphorylation of the tumor 
suppressor p53. Activated p53 in turn, transcriptionally silences the G1/S-transition 
promoting cyclin/CDK complexes, leading to G1 arrest. S phase checkpoint: This 
checkpoint puts a hold on DNA synthesis in response to DNA damage during S phase 
and ensures completion of DNA replication with a minimum of heritable mutations. The 
two major pathways involved at this checkpoint are ATM/ATR–Chk1/Chk2–CDC25A 
and ATM–NBS1–SMC1. DNA Double -stranded breaks (DSBs) in S-phase trigger the 
ATM mediated phosphorylation of the Chk2 kinase, whereas single stranded DNA (at 
stalled replication forks) triggers ATRR mediated phosphorylation of the Chk1 kinase. 
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The ATM/ATR–Chk1/Chk2–CDC25A pathway transmits the activation signal through a 
protein cascade to ultimately inactivate the S-phase-promoting Cyclin E/cdk2 complex, 
thus, preventing replication origin firing, and arresting replicative DNA synthesis. In 
response to DNA DSBs, ATM also phosphorylates NBS1 to activate the MRE11- 
RAD50- NBS1 (MRN) mediated DSB repair pathways. The mitotic G2/M phase 
checkpoint: This checkpoint prevents segregation of damaged chromosomes. Following 
DNA damage, ATM/ATR–Chk1/Chk2–CDC25A pathways activate a downstream 
protein cascade that works through p53-dependent mechanisms to cause G2 arrest that 
prevents cells from enetering mitosis (Houtgraaf et al., 2006; Ishikawa et al., 2006; 
Kastan and Bartek, 2004; Li and Zou, 2005; Shimada and Nakanishi, 2006).  
Deregulation of one or more of these caretaker pathways can lead to genetic 
aberrations such as specific gene mutations or amplifications, deletions or rearrangements 
of chromosome segments, and gain or loss of entire chromosome(s) (Ferguson et al., 
2015). Cancer cells downregulate these very caretaker pathways to further increase the 
frequency with which they acquire genetic aberrations. The “mutator phenotype” 
hypothesis for carcinogenesis postulates that the mutation rate in the early stages of 
tumor development must be significantly greater than that of normal somatic cells (Loeb 
and Loeb, 1999). Accumulating evidence suggests that tumorigenic cells subvert one or 
more caretaker pathways to fast-track their evolution by accumulating favorable 
genotypes that drive carcinogenesis and metastasis even more rapidly. In fact, the 
majority of genes within the DDR and cell cycle checkpoint pathways have been 
recognized as bonafide tumor suppressors (Hanahan and Weinberg, 2011; Kinzler and 
  5 
Vogelstein, 1997). Accordingly, inherited mutations in caretaker genes are the underlying 
cause of several human genomic instability (GI) syndromes that are characterized by a 
significantly increased risk of developing certain types of cancer compared to the healthy 
population (Table 1). (Ceccaldi et al., 2016a; Ghosal and Chen, 2013; Machado and 
Menck, 1997; Raymond J. Monnat and Sidorova, 2014).  
Table 1. Genomic instability diseases and associated cancers 
DDR 
Pathway 
Gene(s) Mutated Syndrome Cancer 
predisposition 
BER 
 
MUTYH 
 
MUTYH-associated 
polyposis 
Colorectal cancer 
 
MMR MSH2, MSH6, 
MLH1, PMS2 
 
Lynch syndrome, 
Hereditary nonpolyposis 
colorectal cancer (HNPCC) 
Colorectal cancer, 
carcinomas 
NER 
 
XPA, XPB, XPC, 
XPD, XPE, XPF, 
XPG, POLH 
Xeroderma Pigmentosum Squamous and basal 
cell carcinoma, 
melanoma 
NHEJ LIG4 Ligase IV syndrome Lymphoma 
ARTEMIS Radiosensitive severe 
combined immunodeficiency 
(RS-SCID) 
Lymphoma 
HR 
 
BLM Bloom Syndrome (BS) 
 
Carcinoma, 
lymphoma, leukemia 
WRN Werner Syndrome (WS) 
 
Sarcoma 
 
RECQL4 Rothmund Thomson 
Syndrome (RTS) 
Skin cancer, 
osteosarcoma 
ICL repair 
 
FANC-A, -B, -C, 
-E, -F, -G, L, -I, -
D1, -D2, -J, -M, -
N, -O, -P, -Q, -R, 
-S, -T, -U, -V 
Fanconi Anemia (FA) 
 
AML, squamous cell 
carcinoma, 
myelodysplasia 
DNA 
damage 
signaling, 
DSB repair 
ATM Ataxia Telangiectasia (A-T) Leukemia, 
lymphomas, 
breast cancer 
NBS1 Nijmegen breakage 
syndrome 
B cell lymphoma 
ATR Seckel syndrome (SS) AML 
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Studying the clinical and cellular phenotypes observed in GI syndrome patients 
has provided us with significant insights into specific functions of DDR and cell cycle 
checkpoint genes that support genome stability and prevent carcinogenesis. However, the 
complex molecular mechanisms that underlie the DDR and checkpoint response network 
remain incompletely understood.  
1.2 DNA damage response pathways for maintaining genomic stability 
1.2.1 Sources and types of DNA damage 
It is estimated that each of the 1013- 1014 cells in the human body receives 105 to 
106  DNA lesions per day (Swenberg et al., 2011). These lesions can be caused by a 
plethora of endogenous and exogenous sources.  
Endogenous DNA damage: Some endogenous damage arises from agents that 
cause chemical modification of the DNA, whereas others arise from errors made by the 
DNA replication machinery. A few major sources that cause chemical modifications 
include reactive oxygen species (ROS) or reactive alkylating compounds produced in 
various cellular compartments ( such as mitochondria and peroxisomes) as byproducts of 
normal cellular metabolism (Jackson and Loeb, 2001).These reactive species can mediate 
oxidation, hydrolytic attack or even uncontrolled methylation of the DNA leading to base 
and nucleotide changes. Moreover, byproducts of alcohol or fat metabolism such as 
acetaldehyde can covalently cross link two bases, either on the same DNA strand or on 
the opposite strands resulting in a DNA intra- or inter- strand cross link respectively. 
During DNA replication and DNA recombination, proofreading errors by the 
involved DNA polymerases can cause erroneous nucleotide insertions resulting in 
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mismatched DNA base pairs. Additionally, the DNA replication machinery may stall and 
collapse at natural impediments such as modified nucleotides giving rise to DNA DSBs. 
Moreover, nuclear enzymes such as Topoisomerase II (that normally function to regulate 
DNA supercoiling) can accidentally cleave the DNA at off-target sites to yield DNA 
DSBs as well. (Ceccaldi et al., 2016a; Cortez, 2015; Khanna and Jackson, 2001; 
Rothkamm et al., 2003). 
Exogenous DNA damage: The main naturally occurring DNA damage sources 
include ultraviolet (UV) light and ionizing radiation (IR). UV light causes the formation 
of photoproducts like cyclopyrimidine dimers. Exposure to IR and X-rays causes DNA 
DSBs. A multitude of chemical genotoxic agents such as cisplatin, diepoxybutane, 
mitomycin C (MMC) and bifunctional alkylating agents such as nitrogen mustard can 
cause additional DNA lesions such as intra- or inter-strand crosslinks. Due to their 
particularly high toxicity, these crosslinking agents are frequently used as cancer 
chemotherapeutic drugs.(Swenberg et al., 2011).  
Depending on the type of the DNA damage, cells employ different DDR 
pathways to remove the DNA lesion in a timely and efficient manner, thereby 
maintaining the integrity of the genetic information. (Figure 1.2). 
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Sources of DNA damage and types of damage response pathways 
 
 
Figure 1.1: Sources of DNA damage and associated types of damage response 
pathways 
 Various kinds of DNA damages are resolved by a designated pathway. (i) Alkylating 
agents or other spontaneous reactions in the presence of reactive oxygen species can 
result in alkylated bases or single stranded DNA breaks. These are resolved by the 
BER pathway. (ii) Mis-incorporation of an incorrect base resulting in a mismatched 
base pair can occur during replication due to insufficient proofreading activity by the 
DNA polymerases. These are repaired by the MMR pathway. (iii) UV light or 
polycyclic hydrocarbons can cause intra-strand crosslinks or bulky adducts. These are 
repaired by the NER pathway. (iv) Endogenous aldehydes produced as metabolic 
byproducts or clinically used chemotherapeutic agents like Cisplatin or Mitomycin C 
can induce DNA inter-strand crosslinks. These are repaired by the Fanconi Anemia 
Pathway. (v) Multiple genotoxic sources including ionizing radiations, collapsed 
replication forks due to prolonged fork stalling, or even persistently unrepaired DNA 
lesions can result in DNA DSBs. The DSBs are repaired via the error prone NHEJ or 
the relatively error free HR pathway. 
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1.2.2 DNA Repair Pathways- an overview 
DNA Excision repair pathways: 
 (i) The Base Excision Repair (BER) pathway. 
  The BER pathway repairs the majority of hydrolytic decay- mediated deamination 
events and bulky chemical modifications (such as methylation or oxidation) that occur at 
the DNA bases or the DNA sugar phosphate backbone. BER excises the damaged base 
carrying to create an abasic site, followed by incisions of the sugar phosphate backbone 
and replacement of the previously damaged nucleotide with an intact nucleotide. Biallelic 
mutations in BER pathway genes cause predisposition to recessively inherited 
adenomatous polyposis and colon cancer (Kim and Wilson, 2012; Krokan and Bjørås, 
2013; Robertson et al., 2009).  
(ii) The MisMatch Repair (MMR) pathway. 
 MMR repair is primarily used to repair base-base mismatches and 
insertion/deletion mis-pairings that are generated during normal DNA replication and 
recombination. The MMR pathway also removes mis-incorporated, chemically altered 
nucleotides from DNA (Li, 2008). The MMR pathway proteins identify and bind to the 
mismatched pair on the DNA. The mismatch-containing strand is cleaved to allow for 
removal of the mismatch segment by the concerted effort of an exonuclease/helicase 
complex, followed by resynthesis of the excised DNA tract. Mutations in the MMR 
pathway genes cause a genome instability disease called Lynch Syndrome  (Lee et al., 
2016; Li, 2008; Martín-López and Fishel, 2013). 
(iii) The Nucleotide Excision Repair pathway (NER). 
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The NER pathway primarily recognizes lesions that distort the DNA double helix 
structure. The primary substrates for NER are photoproducts caused by ultraviolet (UV) 
light (such as cyclopyrimidine dimers) and bulky adducts (Marteijn et al., 2014). The 
NER proteins remove a short oligonucleotide stretch from the DNA strand containing the 
lesion and use the undamaged single-stranded DNA as a template to re-synthesize the 
complementary sequence. 
 Mutations in three different NER pathway genes within different sub-class of the 
pathway, are associated with three different GI syndromes. (Xeroderma pigmentosum 
(mutations in global NER pathway genes), Cockayne syndrome (mutations in Cockayne 
syndrome NER pathway genes) and trichothiodystrophy (mutations in transcription 
coupled NER pathway genes). (Balajee and Bohr, 2000; Marteijn et al., 2014; Reed, 
2011; Schärer, 2013).  
DNA double strand break (DSB) repair pathways:  
A DNA DSB occurs when the opposite strands of the DNA double helix are 
severed. DNA DSBs represent a particularly dangerous type of DNA damage that - when 
unrepaired or inaccurately repaired- can eventually lead to chromosomal aberrations 
including breaks, translocations and deletions. Human cells possess two distinct DNA 
DSB repair pathways- Non Homologous End Joining (NHEJ) and Homologous 
Recombination (HR) repair (Ceccaldi et al., 2016b; Jasin and Rothstein, 2013; 
Rothkamm et al., 2003).  
The NHEJ pathway is the primary DSB repair pathway in human cells and 
functions predominantly in the G1 phase of the cell cycle. The NHEJ machinery 
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recognizes a DSB, holds the termini together while performing limited degradation of 
these ends and eventually ligates even mismatched and non-cohesive broken ends of 
DNA back together. Since NHEJ does not rely on a homologous template for break repair 
it is considered to be highly error-prone (Davis and Chen, 2013; Gaymes et al., 2002; 
Lieber, 2010; Lieber et al., 2003).  
In contrast, the HR repair pathway functions in the S-phase of the cell cycle, relies 
on DNA sequence homology and is therefore considered to be relatively error-free. For 
HR repair, both 5’ ends of a DNA DSB are resected by nucleases to produce long 3’ 
ssDNA overhangs. Subsequently, one of the 3’ ends invades the intact sister chromatid, 
searches for the complementary sequence and uses it as the template to extend itself. The 
second end of the DSB is engaged, by either second end capture through DNA annealing 
or a second invasion event. Ultimately, the invaded strand is resolved or dissolved to 
individual chromatids by a group of proteins as discussed later in this chapter (Bachrati 
and Hickson, 2009; Jasin and Rothstein, 2013; Khanna and Jackson, 2001; Renkawitz et 
al., 2014; Sung and Klein, 2006).  
The DNA interstrand crosslink repair pathway:  
A DNA inter strand crosslink (ICL) is a covalent link between the Watson and 
Crick strands of the DNA double helix. DNA ICLs are particularly toxic to cells as they 
represent physical barriers to the DNA replication and DNA transcription machineries.  
The repair of DNA ICLs relies heavily on the Fanconi Anemia (FA) pathway. 
Complete ICL removal requires concerted actions between the FA proteins and members 
of several other DNA repair pathways including NER and HR repair factors. In S-phase, 
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the FA pathway proteins incise and remove the ICL with assistance from the NER 
pathway members. The ensuing DSB is then repaired by the HR repair machinery. (Kee 
and D’Andrea, 2012; Wang, 2007). The details of DNA ICL repair are discussed in in the 
subsequent pages of this chapter.  
Chromatin reorganization in the context of DNA damage repair: 
In human cells, the genomic DNA is packaged with histones complexes into a 
highly ordered structure, the chromatin. Chromatin consists of repeating units called the 
nucleosomes. Each nucleosome is a nucleoprotein assembly comprised of 146 bp of 
DNA wrapped approximately two times around a histone octamer comprising two 
histone H2A-H2B dimers and a histone H3-H4 tetramer (Polo, 2015; Seeber and Gasser, 
2016; Tagami et al., 2004). The role of chromatin reorganization during the cellular DNA 
damage response is best explained by the “Access-Repair-Restore” model described by 
Soria et. al., 2012. This model describes the chromatin as an integration platform 
orchestrating the maintenance of cellular functions while coordinating the DDR 
pathways. Strictly regulated chromatin disorganization events such as histone eviction 
and nucleosome sliding at sites of DNA damage are crucial to provide the DDR pathway 
members access to the DNA lesion. Following the repair of the DNA lesion, the DDR 
machinery dissociates from the DNA and the ordered chromatinized state is restored. 
Chromatin access and restoration are mediated by the concerted actions of the 
multifaceted and complex chromatin organization machinery that consists of chromatin 
remodelers, histone chaperones and histone modifying enzymes (Polo, 2015; Soria et al., 
2012). One such example of chromatin reorganization has been well described in the 
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context of DSB repair. Following DNA DSB induction, the histone acetyl transferase 
TIP60 is recruited to the chromatin surrounding the DSB by docking onto histone H3 
proteins that are trimethylated at lysine 9 (H3K9me3). Once recruited, TIP60 promotes 
histone H4 acetylation, which in turn creates open chromatin structures to facilitate 
access to DNA DSB repair proteins (Jacquet et al., 2016; Seeber and Gasser, 2016). 
Simultaneously, TIP60 acetylates and activates the ATM kinase that subsequently 
initiates the downstream events of DSB repair. Once the repair is initiated, the process of 
chromatin restoration starts concomitantly, which involves histone chaperones such as 
ASF1, CAF1 and possibly the ATRX/DAXX complex for histone deposition and re-
chromatinization (Adam et al., 2014; Polo et al., 2006).  
Thus, the coordinated actions of the chromatin reorganization machinery and the 
DDR machinery are important for the successful repair of DNA lesions (Hunt et al., 
2013).  
1.3 The Fanconi Anemia pathway and DNA ICL repair 
1.3.1 Fanconi Anemia – clinical and cellular phenotypes 
Fanconi Anemia (FA) is a rare, highly heterogeneous inherited GI syndrome (1 in 
100,000 people). To date, homozygous mutations in 21 different FA genes have been 
identified as causative of FA (Ceccaldi et al., 2016a; Walden and Deans, 2014). FA 
patients present with a complex spectrum of pathological manifestations (Kee and 
D’Andrea, 2012; Walden and Deans, 2014; Wang, 2007). Hematological defects include 
severe bone marrow failure, aplastic anemia, myelodysplastic syndrome, acute myeloid 
leukemia (AML) and pancytopenia. Other symptoms include multiple congenital 
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abnormalities such as skeletal defects, skin hyperpigmentation, osteopenia, endocrine and 
gastrointestinal abnormalities (D’Andrea and Grompe, 2003; Kee and D’Andrea, 2012). 
Moreover, FA adults who survive the childhood bone marrow failure via a successful 
bone marrow transplant show a very high incidence of squamous cell carcinomas. 
FA patient cells show a delayed proliferation rate and an abnormal cell cycle 
distribution with a prolonged S phase (Akkari et al., 2001). Moreover, FA cells are highly 
sensitive to DNA interstand crosslinking agents such as MMC (Boisvert and Howlett, 
2014; D’Andrea and Grompe, 2003; Garcia-Higuera et al., 2001). Upon treatment with 
DNA ICL inducing agents, FA cells fail to arrest during S-phase and consequently 
accumulate in the G2/M phase of the cell cycle, a phenomenon that is used as the 
diagnostic tool for FA. In addition, FA patient cells show spontaneous chromosomal 
aberrations including chromosome breaks, gaps and radial formations, that are further 
exacerbated upon DNA ICL induction.  
1.4 The FA pathway and DNA ICL repair 
DNA ICLs are predominantly recognized during S-phase, when two moving 
replication forks converge at the ICLs (Duxin and Walter, 2015; Knipscheer et al., 2009; 
Räschle et al., 2008). Per the current FA pathway model, the FA proteins act in a linear 
hierarchy during DNA ICL repair and can be broadly divided into three tiers: an upstream 
FA core complex (Tier I), a central heterodimer composed of FANCD2 and FANCI (Tier 
II) and several downstream FA proteins (Tier III) (Figure. 1.2) (Ceccaldi et al., 2016a; 
D’Andrea and Grompe, 2003; Kee and D’Andrea, 2012; Walden and Deans, 2014; 
Wang, 2007).  
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FA pathway proteins 
 
 
 
 
 
 
Figure 1.2: Proteins in the FA pathway 
The FA pathway comprises 21 different proteins that can be distributed into three broad 
groups based on their function within the pathway. Tier I of FA pathway consists of FANCM 
and the FA core complex proteins that function as an E3 Ubiquitin ligase. UBE2T and 
FANCL are the catalytic subunits for the E2 and E3 ubiquitin ligase activity. Tier II is 
comprised of the FANCD2-FANCI (ID2) complex, which itself gets monoubiquitinated by 
Tier I proteins. Tier III of FA pathway comprises the downstream factors, that can be sub-
classified as nucleases, TLS polymerase or homologous recombination repair factors. The ID2 
complex facilitates the recruitment of the downstream Tier III proteins to facilitate ICL repair. 
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The FA pathway-mediated DNA ICL repair occurs in several steps as detailed below. 
STEP I: Recognition of the DNA ICL by the upstream FA core complex  
(Figure 1.3 i- iii): 
Upon replication fork stalling at a DNA ICL, the replicative helicase complex 
MCM2-7 is evicted from the stalled fork. Subsequently, the FA core complex member 
FANCM, in complex with the FA- associated protein 24 (FAAP24) and the histone fold 
proteins MHF1 and MHF2, is recruited to the ICL (Kim et al., 2008a). Once bound to the 
ICL, the FANCM-MHF-FAAP24 complex then assembles the complete FA core 
complex consisting of FANCA, -B, -C, -E, -F, -G, -L and -T (Hira et al., 2015; Hodson 
and Walden, 2012; Huang et al., 2014; Kim et al., 2008a; Rickman et al., 2015).  
 
STEP II: Activation of the central FANCD2-FANCI heterodimer by monoubiquitination 
(Fig. 1.3 iv): 
Once the FA core complex is fully assembled at the DNA ICL, it promotes the 
recruitment of the FANCD2-FANCI heterodimer (called the ID2 complex). The FA core 
complex then acts as an E3 ubiquitin ligase – with FANCL as the catalytic subunit - that 
monoubiquitinates both members of the ID2 complex (ID2Ub) (Alpi et al., 2008). This 
step is indispensable for DNA ICL repair and is considered to be the key activation step 
of the FA pathway. (Garcia-Higuera et al., 2001; Garner and Smogorzewska, 2011; 
Gibbs-Seymour et al., 2015; Rajendra et al., 2014; Wang et al., 2004). Once activated, the 
chromatin-bound ID2Ub complex orchestrates the recruitment of downstream FA and 
non-FA proteins for ICL repair, as detailed below. 
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STEP III: Generating dual incisions at the DNA ICL site 
(Fig. 1.3 v): 
In order to remove the ICL lesion, incisions must be made on the same DNA 
strand on either side of the ICL. To this end, the ID2Ub complex facilitates the recruitment 
of FANCP/SLX4 (Synthetic lethal of unknown function protein 4) that acts as a docking 
platform for several DNA endonucleases including FANCQ/XPF-ERCC1 (Klein Douwel 
et al., 2014). FANCQ promotes the incision of the 3’ side of the DNA ICL containing 
DNA. While it is currently not known which endonuclease is performing the incision on 
the other side of the DNA ICL, several endonucleases may be able to perform this role, 
including the SLX4-dependent endonucleases- SLX1 or MUS81-EME1, or the FAN1 
nuclease (Fanconi Associated Nuclease 1) that are known to be recruited to DNA ICL- 
containing chromatin in an ID2Ub-dependent manner. (Ceccaldi et al., 2016a; Kang, 2011; 
Kim et al., 2012b; Klein Douwel et al., 2014; Kratz et al., 2010; MacKay et al., 2010; 
Smogorzewska et al., 2010; Stoepker et al., 2011). The “unhooking” of the ICL results in 
a two ended DSB on the incised strand (Fig. 1.3 v) (Duxin and Walter, 2015), while the 
other DNA strand contains gapped dsDNA with the bulky ICL still attached (Fig. 1.3 vi).  
 
STEP IV: ICL lesion bypass and gap filling DNA synthesis  
(Fig 1.3 vi): 
The gap filling DNA synthesis across the bulky ICL cannot be carried out by 
either of the main replicative DNA polymerases, epsilon or delta, since the ICL adduct 
will block synthesis of the complementary DNA strand. To bypass such unusual DNA 
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lesions, cells employ a range of so-called translesion synthesis (TLS) DNA polymerases 
that represent low fidelity DNA polymerases with a bigger substrate binding pocket. 
These polymerases can insert a nucleotide across the ICL mono-adduct and thus, bypass 
the lesion. 
The recruitment of the TLS polymerases is dependent on both, the FA core 
complex and FANCD2 (Fu et al., 2013; Kim et al., 2012a). The specific polymerase(s) 
that carry out the insertion step of adding the nucleotide complementary to the bulky ICL 
adduct, are still unknown. The insertion step is followed by extension of this abnormal 
primer template by the Rev1 and Polζ polymerase complex followed by the removal of 
the remaining ICL mono-adduct by one of the cellular excision repair pathways in the 
cell. Once restored, this intact chromatid can now serve as a template for HR mediated 
repair of the two ended DNA DSB on the other sister chromatid (Haynes et al., 2015). 
The remaining ICL mono-adduct is predicted to be removed by one of the excision repair 
pathways in the cell. 
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FA pathway mediated ICL repair 
 
 
                                                       
 
Figure 1.3: Mechanism of ICL repair by the FA pathway- 
The 21 proteins that constitute the FA pathway work in a coherent manner to mediate ICL repair. 
(i) During replication, moving forks on either side of the ICL (indicated in red) converge at the 
ICL. (ii) The replicative helicase MCM 2-7 complex is evicted from the forks. (iii) FANCM 
recognizes the ICL and mediates the activation and recruitment of the FA core complex. (iv) The 
FA core complex mediates the chromatin recruitment and ubiquitination of FANCD2-FANCI 
complex. (v) Chromatin bound FANCD2 recruits the nucleases SLX4 and XPF and mediates 
incision across the ICL on one sister chromatid. (vi) The ICL is flipped out and TLS polymerases 
synthesize DNA and bypass the lesion on one chromatid. (vii) The resulting DSB in the other 
sister chromatid is now repaired via the HR pathway proteins 
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STEP V: Repair of the DNA DSB by the HR pathway  
(Fig 1.3- Step (vi), Figure. 1.4): 
The HR machinery that is responsible for repairing the DSB generated by the dual 
ICL incision step is composed of both FA and non FA pathway components. FANCD2 
has been shown to participate at multiple steps within this process, as described below. 
BRCA1/FANCS is a key initiator of the HR machinery along with the nuclease complex 
MRN (MRE11/RAD50/NBS1). (Escribano-Díaz et al., 2013). BRCA1 and MRE11, 
along with FANCD2 recruit CtIP (CtBP-interacting protein). CtIP forms a complex with 
FANCD2 and MRE11 and promotes the resection of the 5’ ends at the DSB to generate 
3’ single stranded DNA (ssDNA) overhangs (Buis et al., 2012; Escribano-Díaz et al., 
2013; Yeo et al., 2014). At the resected DNA, BRCA1 and FANCD2 then recruit the 
FANCD1/BRCA2 (Breast Cancer Associated 2) and FANCN/PALB2 (Partner And 
Localizer of BRCA2) complex proteins. Subsequently, BRCA2 recruits FANCR/RAD51 
and promotes the formation of RAD51-coated ssDNA nucleofilaments, with assistance 
from other RAD51 paralogues, including FANCO/RAD51 and XRCC2/FANCU 
(Buisson et al., 2010; Escribano-Díaz et al., 2013; Liu et al., 2004). The RAD51 
nucleofilaments catalyze strand invasion of a homologous DNA template (the sister 
chromatid) and perform homology search in the form of a “D-loop” structure. The 
invading ssDNA is then extended by the DNA polymerases using the homologous sister 
chromatid DNA sequence as the template. Second end capture through DNA annealing or 
a second invasion event engages the second end of the DSBs, thus, resulting in a four-
way junction called a Holliday Junction. The Holliday junction can then itself undergo 2 
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fates: 1) it can now be resolved by the nucleases- SLX1/MUS81/EME1 to result in 
crossover products or 2) it can be dissolved by the Bloom helicase (BLM) complex to 
result in a non- crossover product (Bachrati and Hickson, 2009; Kang, 2011; Sung and 
Klein, 2006). The BLM helicase complex is further supported by the FANCJ/BRIP1 
(BRCA1-Interacting Protein 1) -5’-3’ DNA helicase (Cantor and Xie, 2010; Litman et al., 
2005; Suhasini and Brosh, 2012). 
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HR repair pathway 
 
 
 
 
Figure 1.4: Mechanism of HR repair pathway 
After a DSB occurs, BRCA1 and MRE11 mediate the recruitment of CtIP to the DSBs. The 
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Mre11-CtIP complex promotes resection of 5’ ends of the DNA to generate 3’ overhangs. 
BRCA2 and PALB2 mediate the recruitment of RAD51 to this 3’ resected DNA in conjunction 
with the RAD51 paralogs including RAD51C and XRCC2. The RAD51 filament (filled circles) 
coated 3’ strand invades the sister chromatid and conducts homology search. A displacement loop 
(D-loop) is formed during strand invasion between the invading 3' overhang strand and the 
homologous chromatid. Subsequently, DNA polymerase synthesizes the complimentary DNA 
sequence using the homologous chromatid template, converting the D-loop to a Holliday junction 
structure. The second end capture through DNA annealing or a second invasion event 
creates a double Holliday Junction (DHJ) structure.  The DHJ can be dissolved by the 
“dissolvasome” Bloom helicase complex (BLMcx) to give non crossover product. Alternatively, 
the DHJ can be resolved by nucleases- (SLX4-SLX1-MUS81-EME1). Based on the orientation of 
the incisions, the DHJ can be resolved to give crossover or non- crossover products. 
 
 
DNA ICL removal requires an additional novel FANCD2 function 
Two recent studies unveiled an additional mechanism by which FANCD2 
promotes DNA ICL repair. Sato et al. (2012, 2014) identified FANCD2 as a histone H3 
chaperone. The authors showed that recombinant FANCD2 interacted directly with the 
histone H3/H4 tetramer and promoted complete nucleosome assembly in vitro. 
Furthermore, human FANCD2 mediated histone mobilization in living cells following 
DNA ICL induction. Strikingly, the authors showed that two FA-D2 patient-derived, 
histone H3 chaperone-inactive mutants, hFANCD2-R302W and hFANCD2-L231R, were 
unable to promote cellular resistance to DNA ICLs. These findings indicate that 
FANCD2’s histone chaperone activity is crucial for ICL repair and hint that FANCD2 
may functionally interconnect the cellular pathways for DNA repair and pathways that 
regulate nucleosome and chromatin structure. It is intriguing in this context that 
FANCD2 has been reported to interact with the chromatin modifier and histone 
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acetyltransferase TIP60 that is essential for the repair of DNA DSBs including those 
generated at DNA ICLs (Hejna et al., 2008; Jacquet et al., 2016). However, whether 
FANCD2 needs to interact with TIP60 or other chromatin remodelers to promote its 
cellular functions including DNA ICL repair, is not known.  
1.5 Non-canonical roles of the FA pathway 
The FA pathway has crucial, ICL repair-independent functions in S-phase 
In recent years, we have gained insights into additional, non-canonical functions 
of FA pathway members during S-phase and the replication stress response. Importantly, 
FANCD2Ub formation and colocalization with other DNA repair factors such as BRCA2 
and RAD51 was shown to occur during every normal S-phase of the cell cycle. 
(Taniguchi et al., 2002a). Moreover, Sobeck et al. previously reported that FANCD2 and 
FANCA accumulated on normally replicating chromatin in Xenopus S-phase egg extracts 
(Sobeck et al., 2006), suggesting that (at least some) FA pathway members function 
during DNA replication even in the absence of DNA ICLs. In fact, FANCD2 was shown 
to be required for the efficient initiation of DNA replication in primary human fibroblasts 
(Song et al., 2010).  
Several additional functions have been found for FANCD2 and FANCI during the 
cellular replication stress response. FANCD2 and FANCI were shown to associate with 
HU-stalled replication forks, using the iPOND technology (isolation of proteins on 
nascent DNA) (Sirbu et al., 2013). In fact, FANCD2 was found to interact with the 
replicative helicase MCM2-7 complex (Lossaint et al., 2013) and the replicative 
polymerase clamp loader, Proliferating Cell Nuclear Antigen (PCNA) following 
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replication fork stalling, hinting at important roles for FANCD2 at stalled replication 
forks (Howlett et al., 2005). 
Indeed, our laboratory and others recently employed the power of DNA fiber 
assay techniques to study replication events at a single molecule level to reveal novel 
functions for the FA pathway at replication forks stalled in the presence of the replication 
inhibitors hydroxyurea (HU) or aphidicolin (APH). It is now clear that FANCD2 has dual 
roles at these stalled replication forks. A) Fork protection: FANCD2 is required to protect 
nascent DNA strands at stalled replication forks from nucleolytic degradation by 
nucleases such as MRE11 or FAN1. FANCD2 shares these roles with the upstream FA 
core complex and several downstream FA proteins including FANCR/RAD51 and 
FANCD1/BRCA2 (Chaudhury et al., 2013, 2014, Schlacher et al., 2011, 2012; Ying et 
al., 2012). b) Fork restart: FANCD2 coordinates with BLM, CtIP and FAN1 to mediate 
restart of the stalled replication forks, while simultaneously suppressing the firing of new 
replication origins (Chaudhury et al., 2013, 2014, 2014; Davies et al., 2007; Yeo et al., 
2014). Intriguingly, we observed that BLM, CtIP and FAN1 show a preferential 
interaction with the non-ubiquitinated FANCD2 isoform, hinting that – quite 
unexpectedly - the non-ubiquitinated FANCD2 isoform may have functions at stalled 
replication forks (Figure 1.5). Additionally, our studies showed that FANCD2 regulates 
the BLM complex recruitment to stalled forks independently of FANCI (Chaudhury et 
al., 2013), suggesting that FANCD2, and possibly other FA proteins, may have distinct 
and unique roles in the context of replication fork recovery 
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Roles of FA pathway at stalled replication forks 
 
 Figure 1.5: Known roles of FA pathway proteins at stalled replication forks 
Following replication fork stalling, FANCD2 (D2) is recruited to the stalled fork. Here, 
FANCD2 fulfills two distinct functions: (a) it along with FANCA (A), recruits BRCA2 and 
stabilizes RAD51 (red circles-Rad51 nucleofilament) at the fork to prevent fork degradation and 
(b) it recruits the BLM complex (BLMcx), CtIP, RAD51 and FAN1 at the fork to promote fork 
restart and to suppress firing of new replication origins. 
 
1.6 Rationale 
The bone marrow failure and cancer proneness seen in FA patients has been 
attributed to the underlying defect in maintaining genome stability. Until recently, the FA 
pathway was thought to contribute to genome stability solely via its role in DNA ICL 
repair. However, emerging evidence from our laboratory and others strongly supports a 
model where FANCD2 has novel roles at HU- or APH-stalled replication forks that are 
independent of its functions during DNA ICL repair. Our new model raises two very 
important questions as described below. 
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1) Does FANCD2 cooperate with other FA proteins to mediate replication fork 
restart and the suppression of new origin firing? 
As described above, we found that the interactions between FANCD2 and other 
replication fork restart proteins such as BLM, CtIP or FAN1 does not depend on 
FANCD2Ub formation.(Chaudhury et al., 2013, 2014; Yeo et al., 2014). This 
immediately raises the question of whether FANCD2’s role during replication fork restart 
requires the upstream FA core complex whose primary function is to monoubiquitinate 
FANCD2. Moreover, it was previously proposed that downstream FA pathway members 
such as BRCA2 or RAD51 are recruited to chromatin exclusively by FANCD2Ub (Sato et 
al., 2016; Wang et al., 2004), indicating that these proteins should not be able to act in 
concert with the nonubiquitinated FANCD2 isoform. My work described in Chapter 2 
attempted to answer these crucial questions, to dissect monoubiqitination-dependent and -
independent roles of FANCD2 at HU- or APH-stalled replication forks.  
2) How does FANCD2 promote the restart of stalled replication forks?  
There are two different ways in which FANCD2 can be postulated to mediate 
replication fork restart: 
a) FANCD2 may serve as a docking platform for replication restart factors at stalled 
forks: 
FANCD2 appears to interact with and recruit several other replication restart 
factors including BLM, CtIP and FAN1 to stalled replication forks. It is plausible that 
FANCD2 may simply serve as a docking platform to recruit these factors to stalled 
replication forks, thereby promoting fork recovery.  
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b) FANCD2 may contribute to replication fork restart via its H3 chaperone activity 
Two previous studies showed that FANCD2 possesses a histone H3 chaperone 
activity that is indispensable for ICL resistance. This raises the possibility that 
FANCD2’s H3 chaperone activity is also crucial for its role in mediating replication 
restart and suggests that other known histone H3 chaperones may act in concert with 
FANCD2 to fulfill this role. My work described in Chapter 3 attempted to determine if 
FANCD2 functionally interacts with other histone H3 chaperone complexes to promote 
the restart of HU- or APH-stalled replication forks.  
The overall objective of this dissertation is to discover previously unidentified 
roles of individual FA pathway members during the cellular replication stress response. 
Currently, all patients from the twenty-one different FA complementation groups 
undergo similar therapeutic regimens. Understanding the distinct cellular roles of 
individual FA proteins during S-phase is crucial towards the development of personalized 
treatment strategies for FA patients, which should be adjusted depending on the FA gene 
mutated and the type of the individual patient mutation. 
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CHAPTER 2 
 
 
FANCD2, FANCJ and BRCA2 cooperate to promote 
replication fork recovery independently of the Fanconi Anemia 
core complex 
 
(The work in this chapter was published in Raghunandan M., Chaudhury I., Kelich S.L., 
Hanenberg H., and Sobeck A. (2015). Cell Cycle 14, 342–353. PMID: 25659033) 
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Synopsis 
Fanconi Anemia is an inherited multi-gene cancer predisposition syndrome that is 
characterized on the cellular level by a hypersensitivity to DNA ICLs. To repair these 
lesions, the FA pathway proteins are thought to act in a linear hierarchy: Following ICL 
detection, an upstream FA core complex monoubiquitinates the central FA pathway 
members FANCD2 and FANCI, followed by their recruitment to chromatin. Chromatin-
bound monoubiquitinated FANCD2 and FANCI subsequently coordinate DNA repair 
factors including the downstream FA pathway members FANCJ and FANCD1/BRCA2 
to repair the DNA ICL.  Importantly, we recently showed that FANCD2 has additional 
independent roles: it binds chromatin and acts in concert with the BLM helicase complex 
to promote the restart of APH-stalled replication forks, while suppressing the firing of 
new replication origins.  
Here, we show that FANCD2 fulfills these roles independently of the FA core 
complex-mediated monoubiquitination step. Following APH treatment, nonubiquitinated 
FANCD2 accumulates on chromatin, recruits the BLM complex, and promotes robust 
replication fork recovery regardless of the absence or presence of a functional FA core 
complex. In contrast, the downstream FA pathway members FANCJ and BRCA2 share 
FANCD2’s role in replication fork restart and the suppression of new origin firing. Our 
results support a non-linear FA pathway model at stalled replication forks, where the 
nonubiquitinated FANCD2 isoform – in concert with FANCJ and BRCA2 – fulfills a 
specific function in promoting efficient replication fork recovery independently of the FA 
core complex. 
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2.1 Introduction 
Fanconi Anemia (FA) is a recessively inherited genomic instability syndrome 
caused by mutation in any one of twenty one known FA genes (Kee and D’Andrea, 2012; 
Kupfer, 2013). Clinically, FA patients exhibit congenital abnormalities, progressive bone 
marrow failure and a strong predisposition to cancers such as acute myeloid leukemia and 
squamous cell carcinomas. Cells from FA patients are hypersensitive to DNA ICLs and 
show spontaneous chromosomal aberrations that are further exacerbated upon treatment 
with replication-inhibiting agents such as HU or APH (Kee and D’Andrea, 2010; Naim 
and Rosselli, 2009; Schlacher et al., 2012). To promote the repair of DNA ICLs, the 
twenty one FA pathway members are thought to function in a linear hierarchy that can be 
broadly divided into three tiers: an upstream FA core complex, a central FANCD2-
FANCI protein heterodimer and several downstream FA pathway members including 
breast cancer-associated proteins FANCD1/BRCA2 (breast cancer associated 2), 
FANCN/PALB2 (partner and localizer of BRCA2) and FANCJ/BRIP1 (BRCA1-
interacting protein 1) (Kee and D’Andrea, 2012; Wang, 2007). DNA ICLs are mostly 
repaired in S-phase when they block the progression of replication forks (Clauson et al., 
2013; Knipscheer et al., 2009; Räschle et al., 2008). Detection of an ICL triggers the 
recruitment of the FA core complex [FANCA, -B, -C, -E, -F, -G, -L]. The FA core 
complex has now been identified to be composed of three modules – two ancillary 
modules (FANC- A, G and FANC-C, E, F) with non-redundant functions, and a 
catalytically active module (FANC- B, L). Once recruited, the coordinated actions of all 
three modules of the FA core complex – with FANCL as the catalytic subunit – enables 
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its function as a multi-subunit E3 ubiquitin ligase that monoubiquitinates both members 
of the central FANCD2-FANCI heterodimer. Monoubiquitinated FANCD2 and FANCI 
are then recruited to chromatin and into DNA repair foci at DNA ICLs (Garcia-Higuera 
et al., 2001; Meetei et al., 2003; Smogorzewska et al., 2007; Timmers et al., 2001). 
Subsequently, chromatin-bound FANCD2 and FANCI are thought to coordinate 
downstream FA nucleases like SLX4/FANCP and XPF(FANCQ)/ERCC1 with FANCJ, 
BRCA2 and FANCN to mediate incisions at the DNA ICL followed by HR repair of the 
newly generated DNA DSB (Crossan et al., 2011; Kim et al., 2008b; Klein Douwel et al., 
2014; Stoepker et al., 2011; Walden and Deans, 2014; Yamamoto et al., 2011). 
  Recent studies from our laboratory and others revealed novel FA pathway 
functions at replication forks that are stalled in the presence of HU or APH. The FA core 
complex, FANCD2 and BRCA2 function to protect nascent DNA strands at stalled 
replication forks from nucleolytic degradation (Chaudhury et al., 2013; Schlacher et al., 
2011, 2012; Ying et al., 2012). Importantly, FANCD2 also regulates the BLM helicase 
pathway to mediate restart of the stalled replication forks, while simultaneously 
suppressing the firing of new replication origins (Chaudhury et al., 2013; Yeo et al., 
2014). Intriguingly, our previous findings also showed that FANCD2 can recruit and 
assemble BLM pathway members such as BLM and Topoisomerase III (Top3A) on 
chromatin independently of FANCI, indicating a separation of function between these 
two central FA pathway members (Chaudhury et al., 2013). Consequently, these results 
raised the question of whether FANCD2 fulfills its new role in replication fork recovery 
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in concert with – or independently of – the upstream FA core complex and the 
downstream FA pathway members.  
In the current study, we show that – unlike FANCD2 – the FA core complex 
members FANCA, FANCC, FANCG and FANCL are dispensable for the restart of APH-
stalled replication forks and the suppression of new origin firing. FA core complex-
deficient cells recruit nonubiquitinated FANCD2 to chromatin after APH treatment, 
followed by FANCD2-dependent assembly of fork restart factors and robust replication 
fork recovery. In contrast, cells lacking downstream FA pathway members FANCJ or 
BRCA2 fail to restart APH-stalled replication forks, and show a significant increase in 
new replication origin firing. Our results strongly support a novel, non-linear FA pathway 
model where nonubiquitinated FANCD2, FANCJ and BRCA2 act cooperatively, but 
completely independently of the FA core complex to coordinate molecular actions of the 
replication fork restart machinery. 
2.2 Results 
The FA core complex is dispensable for the restart of APH-stalled replication forks 
Using a dual labeling DNA fiber assay, we recently showed that FANCD2 
promotes the restart of APH-stalled replication forks, while simultaneously suppressing 
new origin firing (Chaudhury et al., 2013; Yeo et al., 2014).  In this assay, replication 
tracts are first labeled with DigUTP for 25 min, treated without or with 30 M APH for 6 
hours to cause replication fork arrest, followed by second labeling with BioUTP for 40 
min (Fig. 2.1A). Reproducibly, FANCD2-deficient patient cells show an approximately 
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2.5-fold reduction in replication fork restart efficiency (Fig. 2.1B), accompanied by an 
approximately 4.5-fold increase in new origin firing events (Fig. 2.1B).  
Figure 2.1 
 
Figure 2.1: FANCD2 is essential to mediate replication fork restart  
(A) Representative images of DNA fibers accompanied with a schematic of defining sites of 
replication. (B) Replication fork restart efficiencies were compared between FANCD2-
proficient (PD20+FANCD2WT) and -deficient (PD20) cells. Replication restart efficiency was 
measured as the number of restarted replication forks after APH-mediated fork stalling (DigU-
BioU tracts), compared with the total number of DigU-labeled tracts (DigU + DigU-BioU). (C) 
The number of new sites of replication originating during the 40 min recovery period after APH 
treatment was compared between PD20+FANCD2WT and PD20 cells. New origins of 
replication were measured as the number of green-only (BioU) tracts per unit length. 
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To investigate if these mechanisms depend on the FA core complex that is 
thought to act upstream of FANCD2, we considered that this complex is composed of 
three subcomplexes: two ancillary modules FANCA-FANCG and FANCC-FANCE-
FANCF, and the actual catalytic module FANCB-FANCL (Fig. 2.2A) (Hodson and 
Walden, 2012; Huang et al., 2014; Medhurst et al., 2006; Rajendra et al., 2014). We 
chose FA patient-derived cell lines deficient for FANCA, FANCC and FANCL, each 
lacking one of the three FA core modules, and their isogenic counterparts corrected with 
the respective wild type gene (PD220 and PD220+A, PD331 and PD331+C, 913/1T and 
913/1T+L). We observed robust APH-induced FANCD2 monoubiquitination in the 
PD220+A, PD331+C and 913/1T+L cells, confirming efficient gene correction (Fig. 
2.2B). Using the same DNA fiber assay described in Fig. 2.1A, we first analyzed 
FANCA- and FANCC-deficient cells for fork restart after APH treatment. We found that 
the proportion of replication forks competent for restart was essentially unaffected in 
cells lacking FANCA or FANCC compared to their corrected counterparts (Fig. 2.2C, i 
and ii); moreover, FANCA- or FANCC-deficient cells did not show a significant increase 
in new origin firing (Fig. 2.2D, i and ii). 
Importantly, recent studies revealed that cells lacking either one of the ancillary 
FA core modules still contain very low amounts of FANCD2Ub, whereas cells deficient 
for the catalytic core module do not (Huang et al., 2014; Rajendra et al., 2014). Thus, we 
next tested if FANCL-deficient cells are capable of replication fork recovery after APH 
treatment. Strikingly, the FA patient-derived FANCL-deficient cells exhibited normal 
replication fork restart efficiencies and robust suppression of new origin firing, 
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comparable to the corrected cells (Fig. 2.2C, iii; Fig. 2.2D, iii). Moreover, a genetically 
engineered human FANCL knockout cell line (HCT116/FANCL-/-) showed no defects in 
replication fork restart and no increase in new origin firing after APH treatment 
compared to wild type HCT116 cells (Fig. 2.3 A-C).  
Figure 2.2 
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Figure 2.2: The three FA core sub-complexes are dispensable for the restart of APH-stalled 
replication forks.  
(A) Schematic representation of the three FA core sub-complexes: FANCA-FANCG, FANCC-
FANCE-FANCF, and FANCB-FANCL. FA patient-derived cell lines lacking FANCA, FANCC, 
or FANCLwere used to represent cells deficient for the respective FA core sub complex. (B) 
WCEs from untreated or APH-treated, isogenic cell pairs that were either proficient or deficient 
for FANCA (lanes 1-4), FANCC (lanes 5-8) or FANCL (lanes 9-12) were analyzed for the 
presence of FANCD2 and FANCD2Ub. Tubulin, loading control. (C) Replication fork restart 
efficiencies after APH treatment was compared between isogenic cell pairs proficient or deficient 
for (i) FANCA, (ii) FANCC or (iii) FANCL. (D) The number of new replication sites originating 
during BioU labeling after APH treatment was compared between isogenic cell pairs proficient or 
deficient for (i) FANCA, (ii) FANCC or (iii) FANCL. 
 
 
Figure 2.3 
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Figure 2.3: FANCL knockout cells are competent for replication fork recovery  
(A) APH triggers weak FANCD2 monoubiquitination in HCT116 wild type cells. WCEs from 
untreated or APH-treated HCT116 WT or HCT116 FANCL-/- cells were analyzed for the 
presence of FANCD2 and FANCD2Ub. Tubulin, loading control. (B, C) FANCL is dispensable 
for replication fork restart and suppression of new origin firing. (B) Replication fork restart 
efficiencies after APH treatment were compared between wild type and FANCL-/- cells. (C) The 
number of new replication sites originating during Bio-U labeling after APH treatment was 
compared between wild type and FANCL-/- cells. 
 
Lastly, we argued that FANCG may be required for replication fork recovery, 
since FANCG can act independently of other FA core complex members to regulate 
formation of a separate protein complex (BRCA2-FANCD2-FANCG-XRCC3) (Fig. 
2.4A) (Hussain et al., 2006; Wilson et al., 2008, 2010). However, replication fork restart 
efficiencies and suppression of new origin firing were normal in patient-derived FANCG 
cells compared to wild type cells (Fig. 2.4 B-D), ruling out that FANCG or FANCG-
dependent protein complexes are crucial for these mechanisms.  Taken together, our 
results indicate that the three known FA core complex modules – and thus likely the 
entire FA core complex - are dispensable for the restart of APH-stalled replication forks 
and the simultaneous suppression of new origin firing.  
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Figure 2.4 
 
 
 
Figure 2.4: The BRCA2-FANCD2-FANCG-XRCC3 DNA repair complex is dispensable 
for the recovery of APH-stalled forks. 
 (A) Schematic representation of the BRCA2-FANCD2-FANCG-XRCC3 complex. (B) APH 
triggers efficient FANCD2 monoubiquitination only in FANCG proficient cells. WCEs from 
untreated or APH-treated wild type or FANCG-deficient cells were analyzed for presence of 
FANCD2 and FANCD2Ub. Tubulin, loading control. (C, D) FANCG is dispensable for 
replication fork restart and suppression of new origin firing. (C) Replication fork restart 
efficiency after APH treatment was compared between wild type (GM000637) and FANCG-
deficient (PD352i) cells. (D) The number of new replication sites originating during the Bio-U 
labeling after APH treatment was compared between wild type and FANCG -deficient cells. 
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The nonubiquitinated FANCD2 isoform is crucial for replication fork restart in FA 
core complex-deficient cells 
Our finding that the FA core complex is dispensable for the restart of APH-stalled 
replication forks immediately suggested that the FA core complex-dependent FANCD2Ub 
formation is dispensable for FANCD2’s role during fork recovery. In that case, the 
nonubiquitinated FANCD2 isoform would be responsible for the successful replication 
fork restart observed in FA core complex-deficient cells. To test this, we treated 
PD331+C or PD331 cells with control siRNA or FANCD2 siRNA to generate wild type, 
FANCC-, FANCD2-, or FANCC/FANCD2 double-deficient cells, followed by dual-label 
DNA fiber analysis (Fig. 2.5A). As expected, wild type and FANCC-deficient cells 
exhibited normal replication fork restart efficiencies (Fig. 2.5B, wild type: 78.4%; 
FANCC-deficient: 74.4%) and could suppress new origin firing events (Fig. 2.5C) in 
response to APH. 
 In striking contrast, FANCD2-deficient and FANCC/FANCD2 double-deficient 
cells showed a significant and comparable decrease in fork restart efficiencies (Fig. 
2.5BB, FANCD2-deficient: 37.8%; FANCC/FANCD2 double-deficient: 39.3%) and a 
significant, comparable increase in new origin firing (Fig. 2.5C, ~3.5-fold increase in 
FANCD2- and FANCC/FANCD2 double-deficient cells). Thus, depletion of FANCD2 
renders cells deficient for replication fork restart and suppression of new origin firing, 
irrespective of the absence or presence of a functional FA core complex.  
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Figure 2.5 
 
Figure 2.5: The nonubiquitinated FANCD2 isoform promotes the recovery of APH-stalled 
forks in FA core complex-deficient cells  
(A) WCEs showing the efficiency of siRNA-mediated FANCD2 knockdown in FANCC-
proficient or -deficient cells. Generated cell types: Wild type (PD331+C, siControl), FANCC-
deficient (PD331, siControl), FANCD2-deficient (PD331+C, siFANCD2) and FANCC/FANCD2 
double-deficient (PD331, siFANCD2). Tubulin, loading control. (B) Replication fork restart 
efficiencies after APH treatment were compared between the four cell types described in (A). (C) 
The number of new replication sites originating during BioU labeling after APH treatment was 
compared between the four cell types described in (A). 
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Nonubiquitinated FANCD2 is recruited to chromatin in an APH-responsive manner  
Our results above indicated that cells utilize selectively the nonubiquitinated 
FANCD2 isoform to promote the restart of APH-stalled replication forks. Thus, one 
would expect the nonubiquitinated FANCD2 isoform to accumulate on chromatin in 
response to APH. To test this, we isolated chromatin fractions from FANCC-proficient 
(PD331+C) or -deficient (PD331) cells that had been untreated or treated with APH for 
different lengths of time (2 h, 6 h or 24 h). As expected, FANCC-proficient cells 
contained chromatin-bound FANCD2 even in absence of APH, and showed a continuous 
increase in FANCD2 chromatin binding following APH treatment (Fig. 2.6 A-B) (Sobeck 
et al., 2006; Taniguchi et al., 2002a). In agreement with previous studies, the chromatin 
fractions from FANCC-proficient cells contained predominantly the FANCD2Ub isoform 
(Montes de Oca et al., 2005); however a small amount of nonubiquitinated FANCD2 was 
detectable as well (Fig. 2.6A). Importantly, similar amounts of nonubiquitinated 
FANCD2 were chromatin-bound in FANCC-deficient cells; moreover the 
nonubiquitinated FANCD2 isoform accumulated further on chromatin in response to 
APH treatment (Fig. 2.6B). In addition, we found that Top3A, a member of the BLM 
complex that binds chromatin and promotes replication fork restart in a FANCD2-
dependent manner, exhibited comparable chromatin binding behavior in FANCC-
proficient and -deficient cells (Fig. 2.6A). These results demonstrate that 
nonubiquitinated FANCD2 binds chromatin in an APH-responsive manner and recruits 
BLM complex members independently of the FA core complex. 
 
  43 
Figure 2.6 
 
 
Figure 2.6: Nonubiquitinated FANCD2 is recruited to chromatin in an APH-responsive 
manner 
 (A) FANCC-deficient or -proficient cells were either untreated or treated with APH for the 
indicated time points. Chromatin fractions isolated from these cells were analyzed for the 
presence of FANCD2, FANCD2Ub and Top3A. H2AX, loading control. (B) Immunoblot signals 
for FANCD2 shown the in left panel were analyzed by densitometry and normalized against 
H2AX signals using ImageJ. 
 
A monoubiquitination-dead FANCD2K561R mutant binds chromatin and promotes 
replication fork restart 
To further test the role of FANCD2Ub formation during replication fork restart, we 
analyzed FANCD2-deficient patient cells (PD20) that were complemented with either (i) 
empty vector, (ii) wild type FANCD2 (PD20+FANCD2WT) or (iii) a monoubiquitination-
dead FANCD2 mutant (PD20+FANCD2K561R) (Fig. 2.7A). Interestingly, we found that 
total protein levels of FANCD2K561R were significantly higher than those of FANCD2WT 
in PD20 cells (Fig. 2.7A, compare lanes 2 and 3, or 5 and 6). Concomitantly, both 
FANCD2WT and FANCD2K561R were present in chromatin fractions isolated from 
unperturbed or APH-treated cells, indicating that the FANCD2K561R mutant has residual 
chromatin binding ability (Fig. 2.7B). In agreement with this, the DNA fiber analysis 
revealed that the replication fork restart defect in FANCD2-deficient cells (Fig. 2.7C, 
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PD20: 39.3%) was significantly relieved by expressing FANCD2WT (Fig. 2.7C, 
PD20+FANCD2WT: 84.5%) or the FANCD2K561R mutant (Fig. 2.7C, 
PD20+FANCD2K561R: 74.8%). Simultaneously, the significant increase in new origin 
firing observed in PD20 cells (Fig. 2.7D; ~4.5-fold increase compared to 
PD20+FANCD2WT) was partially suppressed in PD20+FANCD2K561R cells (Fig. 2.7D; 
~2-fold increase compared to PD20+FANCD2WT). Taken together, these results indicate 
that the nonubiquitinated FANCD2 isoform plays a crucial role at sites of APH-stalled 
replication forks to promote fork restart and suppression of new origin firing.  
Figure 2.7 
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Figure 2.7: FANCD2K561R binds chromatin and promotes restart of APH-stalled replication 
forks. 
(A) FANCD2-deficient cells (PD20) complemented with either empty vector, FANCD2WT or 
FANCD2K561R were either untreated or treated with APH, and analyzed for FANCD2 and 
FANCD2Ub. Ku-86, loading control. (B) The three cell types described in (A) were either 
untreated or treated with APH for 6h or 24h, and chromatin fractions from the cells were 
analyzed for the presence of FANCD2 and FANCD2Ub.  Ku-86, loading control. (C) Replication 
fork restart efficiencies after APH treatment were compared between the three cell types 
described in (A). (D) The number of new replication sites originating during BioU labeling after 
APH treatment was compared between the three cell types described in (A). 
 
The “downstream” FA pathway members FANCJ and BRCA2 cooperate with 
FANCD2 to promote replication fork restart 
BRCA1 protein is a critical DNA repair factor that is responsible for the 
recruitment of FANCD2, as well as downstream FA pathway members FANCJ and 
BRCA2, to sites of DNA damage (Garcia-Higuera et al., 2001; Greenberg et al., 2006; 
Wang, 2007). Importantly, we recently showed that BRCA1 also functions upstream of 
FANCD2 to promote the restart of APH-stalled replication forks (Yeo et al., 2014). Thus, 
we asked if the other BRCA1-dependent DNA repair factors, FANCJ and BRCA2, are 
involved in FANCD2-dependent replication fork restart as well. We chose a FANCJ-
deficient patient cell line (752/1T), and its corrected wild type counterpart (752/1T+J). 
Furthermore, we treated 752/1T+J and 752/1T cells with control siRNA or FANCD2 
siRNA to generate wild type, FANCD2-, FANCJ-, or FANCD2/FANCJ double-deficient 
cells, followed by dual-label DNA fiber analysis. As expected, APH treatment induced 
FANCD2Ub formation normally in FANCJ- deficient cells (Fig. 2.8A) (Levitus et al., 
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2005; Litman et al., 2005).  Following APH treatment, the proportion of replication forks 
competent for restart was severely – and equally – reduced in FANCD2- and FANCJ-
deficient cells (Fig. 2.8B, 40.3% and 39.5%). Moreover, this defect in fork restart was not 
further exacerbated in FANCD2/FANCJ double-depleted cells (Fig. 2.8B, 38.8%). In 
parallel, the proportion of newly originated replication tracts increased significantly and 
equally (Fig. 2.8C, ~5-fold) in FANCD2-, FANCJ- and FANCD2/FANCJ double- 
deficient cells compared with wild-type cells. Thus, FANCD2 and FANCJ cooperate to 
promote the recovery of APH-stalled replication forks.  
 
Figure 2.8 
 
. 
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Figure 2.8: Downstream FA pathway protein FANCJ cooperates with FANCD2 for the 
recovery of APH-stalled replication forks.  
(A) WCEs showing the efficiency of siRNA-mediated FANCD2 knockdown in FANCJ-
proficient or -deficient cells. Generated cell types: Wild type (752/1T+J, siControl), FANCD2-
deficient (752/1T+J, siFANCD2), FANCJ-deficient (752/1T, siControl) and FANCD2/FANCJ 
double- deficient (752/1T, siFANCD2). All four cell lines were untreated or treated with APH, 
and WCEs from these cells were analyzed for the presence of FANCJ, FANCD2 and 
FANCD2Ub. Tubulin, loading control. (B) Replication fork restart efficiencies after APH 
treatment were compared between wild type, FANCD2-, FANCJ- and FANCD2/FANCJ double- 
deficient cells (C) The number of new replication sites originating during BioU labeling after 
APH treatment was compared between Wildtype, FANCD2-, FANCJ- and FANCD2/FANCJ 
double-deficient cells 
 
Next, we sought to determine whether BRCA2 promotes replication fork 
recovery, possibly in concert with FANCD2. To this end, we treated a wild type cell line 
(PD331+C) with siControl, siFANCD2, siBRCA2 or siFANCD2/BRCA2 to generate 
wild type, FANCD2-, BRCA2-, or FANCD2/BRCA2 double-deficient cells (Fig. 2.9A). 
As expected, BRCA2-deficient cells were able to support FANCD2Ub formation in 
response to APH treatment.37 DNA fiber analysis revealed that FANCD2- and BRCA2-
deficient cells exhibited strongly – and equally – reduced replication fork restart 
efficiencies (Fig. 2.9B, 40.4% and 39.9% that were not further reduced in the 
FANCD2/BRCA2 double-deficient cells (Fig. 2.9B, 42.1%). Simultaneously, we 
observed that FANCD2-, BRCA2- and FANCD2/BRCA2 double-deficient cells showed 
a significant and similar increase in newly fired replication origins (Fig. 2.9C, ~3-4 fold) 
compared with the wild type cells.  
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Figure 2.9 
 
 
Figure 2.9: Downstream FA pathway protein BRCA2 cooperates with FANCD2 for the 
recovery of APH-stalled replication forks.  
(A) WCEs showing the efficiency of siRNA-mediated FANCD2 and BRCA2 knockdown in 
Wildtype (PD331+C) cells. Generated cell types: Wild type (PD331+C, siControl), FANCD2-
deficient (PD331+C, siFANCD2), BRCA2-deficient (PD331+C, siBRCA2) and 
FANCD2/BRCA2 double-deficient (PD331+C, siFANCD2/siBRCA2). All four cell lines were 
untreated or treated with APH, and WCEs from these cells were analyzed for the presence of 
BRCA2, FANCD2 and FANCD2Ub. Ku-86: loading control.  (B) Replication fork restart 
efficiencies after APH treatment were compared between wild type, FANCD2-, BRCA2- and 
FANCD2/BRCA2 double- deficient cells. (C) The number of new replication sites originating 
during BioU labeling after APH treatment was compared between wild type, FANCD2-, 
BRCA2- and FANCD2/BRCA2 double-deficient cells. 
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Our finding that BRCA2 promotes replication fork restart seemingly contradicts 
two previous studies that used cell lines expressing BRCA2 mutants with C-terminal 
truncations to test the roles of BRCA2 at hydroxyurea (HU)-stalled replication forks. 
Both studies reported that BRCA2 was crucial to protect HU-stalled replication forks 
against nuclease-mediated DNA strand degradation, but was not required to mediate 
replication fork restart (Schlacher et al., 2011; Ying et al., 2012). To address this 
discrepancy, we first sought to exclude the possibility that our findings were due to off-
target effects of the employed BRCA2 siRNA. We repeated the DNA fiber assay in cells 
treated with a second BRCA2 siRNA (siBRCA2#2) that targets a different BRCA2 exon 
(Fig. 2.10A). Following APH-treatment, we observed strongly reduced replication fork 
restart efficiencies (Fig. 2.10B, 37.5%) accompanied by a significant increase in newly 
fired origins (Fig. 2.10C, 3-4-fold) in the siBRCA2#2-treated cells, supporting our initial 
results (Fig. 2.9 A-C) that BRCA2 promotes replication fork restart and the suppression 
of new origin firing. Simultaneously, we found that the siBRCA2#2-treated cells exhibited 
a severe shortening of nascent DNA strands at APH-stalled replication forks compared to 
the wild type cells (Fig. 2.10D), confirming the previous findings that BRCA2 protects 
stalled replication forks from nucleolytic degradation (Schlacher et al., 2011; Ying et al., 
2012).  
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Figure 2.10 
 
Figure 2.10: Cellular treatment with siBRCA2#2 causes severe defects in replication fork 
recovery and in fork stability after APH treatment. 
 (A) Western blot showing the efficiency of BRCA2 knockdown with siBRCA2#2. Wild type 
(PD331+C) cells were treated with siControl or siBRCA2#2, and then either untreated or treated 
with APH. WCEs from these cells were analyzed for the presence of BRCA2, FANCD2 and 
FANCD2Ub. Ku-86, loading control.  (B, C) siBRCA2#2-treatment triggers replication fork 
restart defects after APH treatment. (B) Replication fork restart efficiency after APH treatment 
was compared between siControl or siBRCA2#2 treated cells. (C) The number of new 
replication sites originating during the BioU labeling after APH treatment was compared 
between siControl and siBRCA2#2 treated cells. (D) siBRCA2#2-treatment triggers replication 
fork instability after APH treatment. Lengths of nascent replication fork tracts (labeled with 
DigU only) were measured after 6 h of APH treatment. Preformed DigU tract lengths shorten 
during APH-mediated replication fork stalling in siBRCA2#2 treated cells (median 2.3 µm) 
compared to siControl treated cells (median 4.8 µm). 
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Lastly, we wanted to test if BRCA2’s role in fork restart extends to HU-stalled 
replication forks. We treated cells with siControl or siBRCA2 (Fig. 2.11A), followed by 
DNA fiber analysis. Following HU-treatment, BRCA2-deficient cells exhibited a severe 
reduction in replication fork restart efficiencies (Fig. 2.11B, 35.8%) and showed a 
significant increase in new origin firing (Fig. 2.11C, 4-fold), comparable to those 
phenotypes observed in APH-treated BRCA2-deficient cells (see Fig. 2.9B and C; Fig. 
2.10B and C). Taken together, our results indicate that a complete absence of full length 
BRCA2 causes severe replication fork recovery defects. Moreover, our findings 
demonstrate that BRCA2 acts in concert with FANCD2 to promote the restart of APH- or 
HU-stalled replication forks while simultaneously suppressing the firing of new 
replication origins.  
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Figure 2.11 
 
 
Figure 2.11: BRCA2 is essential for the recovery of HU-stalled replication forks.  
 (A) Western blot showing the efficiency of BRCA2 knockdown with siBRCA2. Wild type 
(PD331+C) cells were treated with siControl or siBRCA2, and then either untreated or treated 
with 4mM HU for 5h. WCEs from these cells were analyzed for the presence of BRCA2, 
FANCD2 and FANCD2Ub. Ku-86, loading control. (B, C) BRCA2 is essential for the recovery 
of HU-stalled replication forks. (B) Replication fork restart efficiencies after HU treatment were 
compared between siControl and siBRCA2 cells. (C) The number of new replication sites 
originating during BioU labeling after HU treatment was compared between siControl and 
siBRCA2 cells. 
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2.3 Discussion 
In this study, we expand on our previous findings that FANCD2 functions in the 
restart of APH-stalled replication forks and the simultaneous suppression of new origin 
firing. Our new results show that FANCD2 shares this role with FA pathway members 
FANCJ and BRCA2, but not with the FA core complex proteins. Our data strongly 
support a non-linear FA pathway model during the recovery of APH-stalled replication 
forks, via mechanisms that depend selectively on the nonubiquitinated isoform of 
FANCD2 (Fig. 2.12).  
The idea that FANCD2 does not rely on the FA core complex to recover stalled 
replication forks is supported by recent findings that FANCD2 binds HU-stalled 
replication forks, where it interacts with the MCM helicase independently of the FA core 
complex protein FANCA (Lossaint et al., 2013; Sirbu et al., 2013). Interestingly, it was 
also shown that FANCD2 and BRCA2 – but not FANCA or FANCC – promote cellular 
resistance to topoisomerase II inhibitors that cause DNA DSBs (Kachnic et al., 2011; 
Treszezamsky et al., 2007). Moreover, FANCD2 is known to promote S-phase 
checkpoint activation in response to ionizing radiation in a manner that depends on 
ATM-mediated FANCD2 phosphorylation but occurs independently of FA core 
complex-mediated FANCD2Ub formation (Taniguchi et al., 2002b). These findings 
indicate a functional separation between FANCD2 and the FA core complex and support 
the idea that FANCD2Ub formation is dispensable not only for replication fork restart, but 
for other FANCD2-dependent functions as well.  
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Figure 2.12 
 
 
Figure 2.12: Distinct FA pathway models during DNA ICL repair versus the restart of an 
APH-stalled replication fork. 
(A) Linear FA pathway model during DNA ICL repair. When replication forks converge at a 
DNA ICL (represented by a red line in the figure), the upstream FA core complex is activated and 
monoubiquitinates FANCD2, followed by its recruitment to the ICL on chromatin. Chromatin-
bound FANCD2Ub then coordinates the actions of downstream DNA repair factors, including 
FANCJ and BRCA2, to facilitate ICL repair. (B) Non-linear FA pathway model during the 
recovery of APH-stalled replication forks. When a single moving replication fork is temporarily 
stalled by APH-treatment, nonubiquitinated FANCD2 is recruited to chromatin independently of 
the FA core complex. Chromatin-bound nonubiquitinated FANCD2 then functions in concert 
with FANCJ and BRCA2 to promote replication fork restart 
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Importantly, in the light of recent findings that only cells lacking the catalytic 
FANCB-FANCL module are truly devoid of any E3 ubiquitin ligase activity towards 
FANCD2, we must assume that the FANCA-, FANCC- and FANCG-deficient cells used 
in our study still contain trace amounts of FANCD2Ub.26,27 Nevertheless, our combined 
findings strongly support a model where replication fork restart occurs independently of 
FANCD2Ub formation: (i) FA patient cells of complementation groups A, C, G and L, as 
well as a human FANCL knockout cell line, are equally competent for replication fork 
restart; (ii) FANCD2WT and FANCD2K561R can both promote replication fork restart at 
similar levels and (iii) nonubiquitinated FANCD2 binds chromatin and recruits other 
replication fork restart proteins in an APH-inducible manner. Interestingly, a recent study 
also showed that human cells lacking the FANCA-FANCG and the FANCC-FANCE-
FANCF module fail to recruit FANCB-FANCL to chromatin and do not contain any 
FANCD2Ub, but still exhibit residual chromatin-bound FANCD2 (Huang et al., 2014). 
Together, these findings strongly indicate that nonubiquitinated FANCD2 is recruited to 
APH-stalled replication forks independently of the FA core complex to promote fork 
restart. At the same time, APH treatment does robustly trigger FANCD2Ub formation; 
moreover, chromatin-bound FANCD2 exists predominantly as the FANCD2Ub isoform, 
even in unperturbed cellular conditions. What then is the role of the FANCD2Ub 
formation in response to APH? Intriguingly, the Jasin laboratory showed that FANCD2 
and FANCA are required to protect nascent DNA strands at HU-stalled replication forks 
from nucleolytic degradation (Schlacher et al., 2012). Thus, the FANCD2Ub isoform may 
specifically function in replication fork protection, whereas nonubiquitinated FANCD2 
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mediates fork restart. These two mechanisms appear to be functionally uncoupled, since 
nascent DNA strand degradation at the stalled fork does not interfere with successful 
restart of DNA synthesis in FA core complex-deficient cells. 
It is noteworthy that while the FANCD2K561R mutant can support replication fork 
restart and suppress new origin firing after APH treatment, it is not as efficient as 
FANCD2WT (see Fig. 2.7C and D). This indicates that the FANCD2K561R mutant has 
additional defects that are not related to its inability to become monoubiquitinated. In 
further support of this idea, we previously found in Xenopus egg extracts that 
xFANCD2K562R – unlike nonubiquitinated xFANCD2WT – fails to stably associate with 
late-replicating chromatin.21 Interestingly, several studies including ours observed that 
FANCD2-deficient cells complemented with the FANCD2WT or FANCD2K561R gene 
constructs contain much higher protein levels of FANCD2K561R than FANCD2WT (see 
Fig. 2.7A), possibly reflecting the cells’ attempt to increase the amount of chromatin-
bound FANCD2K561R (see Fig. 3B). We speculate that transient chromatin interactions of 
FANCD2K561R are sufficient to partially promote replication fork restart and suppression 
of new origin firing.  
In contrast to the FA core complex, at least two of the “downstream” FA pathway 
members, FANCJ and BRCA2, now join the growing group of replication fork restart 
proteins including FANCD2, BRCA1, BLM, MRE11, RAD51 and CtIP (Bryant et al., 
2009; Chaudhury et al., 2013; Petermann et al., 2010; Yeo et al., 2014). Intriguingly, each 
of these proteins has been implicated in HR repair of DNA DSBs, strongly supporting a 
model where the recovery of APH-stalled replication forks involves HR mechanisms. 
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FANCJ’s role in fork recovery is not surprising, since it interacts with known fork 
restart factors including BRCA1, FANCD2 and BLM  (Chen et al., 2014; Davies et al., 
2007; Yeo et al., 2014). In fact, since FANCJ – like FANCD2 – stabilizes BLM in human 
cells, the replication restart defects seen in cells depleted of FANCJ, FANCD2 or both 
may be partly due to a lack of available BLM protein (Chaudhury et al., 2013; Suhasini et 
al., 2011). Unexpectedly however, another study reported only mildly delayed fork restart 
kinetics in FANCJ-deficient chicken DT40 cells (Schwab et al., 2013). However, this 
discrepancy could be due to differences in molecular mechanisms between human and 
chicken cells; moreover, our study analyzed fork restart after a complete DNA synthesis 
block, whereas the conditions used by Schwab et al. allowed continuous slow DNA 
synthesis in presence of HU, which may account for the less severe phenotype observed 
by these authors. 
Our discovery that BRCA2 is required for the restart of APH or HU-stalled 
replication forks seemingly contradicts two previous reports that BRCA2 protects nascent 
DNA strands at stalled replication forks, but is not required for replication fork restart 
(Schlacher et al., 2011; Ying et al., 2012). Importantly, both studies used cells that 
express residual C-terminally truncated BRCA2 proteins: (i) human CAPAN-1 cells 
(BRCA2 truncated after aa 1981), (ii) mouse embryonic stem cells carrying the 
BRCA2lex1/lex2 alleles (BRCA2 truncated after aa 3088/3139), and (iii) V-C8 hamster 
cells (BRCA2 truncated after aa 2494/2567) (Goggins et al., 1996; Morimatsu et al., 
1998; Wiegant et al., 2006). In contrast, we observed severe fork restart defects in 
siBRCA2-depleted cells. This suggests that BRCA2-dependent fork recovery may not 
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require the BRCA2 C-terminus and predicts that separate regions on BRCA2 are 
responsible for its roles in fork protection versus fork restart.  
Lastly, in the context of BRCA2’s new role, it seems counterintuitive that 
FANCG, and thus the FANCG-dependent BRCA2-FANCD2-FANCG-XRCC3 complex 
is dispensable for fork restart, while every complex member other than FANCG is crucial 
for this mechanism (Chaudhury et al., 2013; Petermann et al., 2010). Additional studies 
will be necessary to solve this puzzle.  
In summary, our study reveals a clear separation of function within the three-
tiered FA pathway and demonstrates that FANCD2 and at least two of the “downstream” 
FA pathway proteins fulfill a crucial function at stalled replication forks that is 
completely independent of the FA core complex and its E3 ligase activity. The ability of 
FA core complex-deficient cells to promote fork restart mechanisms that rely heavily on 
FANCD2 and other FA proteins may contribute to the milder phenotypes typically 
associated with inherited mutations in FA core complex genes (Bakker et al., 2013a; Kalb 
et al., 2007).  
2.4 Materials and methods  
Cell lines and cell culture techniques 
PD220 (FANCA-deﬁcient), PD220+A (retrovirally complemented with wild type 
FANCA)57, 58 and PD352i (FANCG-deficient) patient cells (Donahue and Campbell, 
2002; Jakobs et al., 1997) were obtained from the FA Cell Repository at the Oregon 
Health & Science University. GM00637 cells, used as control cell line for assays with 
PD352i cells, were purchased from the Coriell Institute, USA. PD331 (FANCC-deﬁcient) 
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and PD331+C (retrovirally complemented with wild type FANCC) were a gift from Dr. 
Rosselli (Hirano et al., 2005; Naim and Rosselli, 2009). PD20 (FANCD2-deficient), 
PD20+FANCD2WT (complemented with wild type FANCD2) and PD20+FANCD2K561R 
(complemented with monoubiquitination-dead FANCD2 mutant) were a gift from Dr. 
Kupfer (Chen et al., 2014).  In addition, we generated the following cell lines: 913/1T + 
S91IN (FANCL-deficient) and 913/1T + S91FLcoIN (retrovirally complemented with 
wild type FANCL); 752/1T + S91IN (FANCJ-deficient) and 752/1T + S91FJcoIN 
(retrovirally complemented with wild type FANCJ). The 913/1T cells carry two 
heterozygous FANCL mutations (c.1007_1009delTAT = p.I336_C337delinsS; 
g.35021C>G = p.K125_L126insNYELINEKEFR) (Neveling, 2012). The 752/1T cells 
carry a homozygous FANCJ frameshift mutation (c.308delG = pG103fsS). All cells 
described above were cultured in DMEM (GIBCO) with 10% FBS and 1% Penicillin-
Streptomycin.  
HCT116 WT cells and HCT116 FANCL-/- cells were a gift from Dr. Chen 
(Leung et al., 2012). These cells were cultured in Mc Coy's media (Corning) enriched 
with 10% FBS, 1% Pencillin-Streptomycin and 1% Glutamine. Cells were treated with 
Aphidicolin (Sigma; 30M for 6 hours or Hydroxyurea (Sigma; 4mM for 5h) unless 
indicated otherwise.  
 
DNA fiber assay 
We used a DNA ﬁber protocol as previously described (Chaudhury et al., 2013). 
Moving replication forks were labeled with digoxigenin-dUTPs (DigU) for 25min and 
then with biotin-dUTPs (BioU) for 40min. To allow efficient incorporation of the dUTPs, 
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a hypotonic buffer treatment (10mM HEPES, 30mM KCl, pH 7.4) preceded each dUTP-
labeling step. To visualize labeled fibers, cells were mixed with a 10-fold excess of 
unlabeled cells, fixed and dropped onto slides. After cell lysis, DNA fibers were released 
and extended by tilting the slides. Incorporated dUTPs were visualized by 
immunofluorescence detection using anti-digoxigenin-Rhodamine (Roche) and 
streptavidin-Alexa-Fluor-488 (Invitrogen). Images were captured using a Deltavision 
microscope (Applied Precision) and analyzed using Deltavision softWoRx 5.5 software. 
Replication restart efficiency was measured as the number of restarted replication forks 
after APH-mediated fork stalling (DigU-BioU tracts), compared with the total number of 
DigU-labeled tracts (DigU + DigU-BioU). New origins of replication were measured as 
the number of green-only (BioU) tracts per unit length. All DNA ﬁber results are the 
means of two or three independent experiments (300 DNA ﬁbers per experiment). Error 
bars represent the standard error of the mean and signiﬁcance was determined by 
student's t-test. All values for DNA fiber data analysis following recovery from APH 
treatment are provided in Table S1. Statistical signiﬁcance at P<0.01, P<0.001 and 
P<0.0001 is indicated as *, ** and ***, respectively.  
 
siRNA experiments 
iGENOME non-targeting siRNA was used as a control for all siRNA 
experiments. siRNA duplexes for iGENOME non-targeting siRNA and FANCD2 
(sequence- CAACAUACCUCGACUCAUUUU) were purchased from Dharmacon 
research (Thermo Scientiﬁc, MA, USA). Transfections were performed using 
DharmaFECT1 transfection reagent according to the manufacturer’s protocol. siRNA 
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duplex for BRCA2 was purchased from Invitrogen (siBRCA2: BRCA2HSS101095; 
targets exon 10; siBRCA2#2: BRCA2HSS101097; targets exon 18) and transfections were 
performed using RNAiMax lipofectamine reagent according to the manufacturer's 
protocol. All siRNAs were used at a final concentration of 20 nM. 
 
Preparation of whole cell extract (WCEs) and chromatin fractions from human cells  
To prepare whole cell extracts, cells were washed in PBS, resuspended in lysis 
buffer (10mM Tris, pH 7.4, 150mM NaCl, 1% NP-40, 0.5% Sodium Deoxycholate, 1mM 
EDTA, 1mM DTT, complete protease inhibitor cocktail) and incubated on ice for 10 min. 
Cell extracts were centrifuged for 5 min at 10000g, and the supernatant was used for 
further analysis. Chromatin fractions were prepared as described (Ge et al., 2007). 
Briefly, 3x106 cells were washed in PBS, pelleted and resuspended in 1 ml cytoskeleton 
buffer. After 10 min incubation on ice, the suspension was centrifuged at 5000g for 3 
min. The supernatant was discarded and the resultant pellet containing chromatin-bound 
sample was washed 3 times with CSK buffer. The chromatin pellet was resuspended in 
150 l CSK buffer and mixed with equal volume of 2X LDS Nupage LDS sample buffer. 
Samples were sonicated briefly prior to PAGE analysis. 
 
Immunoblotting 
Protein samples were separated on denaturing gradient gels and transferred to 
Immobilon P membranes (Millipore). After blocking in 5% milk, membranes were 
incubated overnight with the primary antibodies. Subsequent incubation with Horseradish 
peroxidase-conjugated rabbit secondary antibodies (Jackson Labs) or mouse secondary 
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antibodies (Bio-Rad) was carried out for 1 hour. Protein bands were visualized using an 
ECL Plus system (Millipore). 
 
Antibodies 
Commercial antibodies were used against human FANCD2 (Santa Cruz, sc-
20022), Tubulin (Abcam, ab7291), H2AX (Bethyl, A300-083A), BRCA2 (Calbiochem, 
OP95), Top3A (Proteintech 14525-1-A), Ku86 (Santa-Cruz, sc-5280). Antibodies were 
used at the following dilutions in WB: FANCD2 (1:1000), BRCA2 (1:500), H2AX 
(1:10000), Tubulin (1:10000), Top3A (1:1000), Ku-86 (1:500). 
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CHAPTER 3 
 
 
A functional interaction between the Fanconi anemia protein 
FANCD2 and the chromatin remodeling factor ATRX 
promotes replication fork recovery. 
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Synopsis 
Fanconi Anemia (FA) is an inherited cancer predisposition syndrome characterized by 
cellular hypersensitivity to DNA interstrand crosslinks (ICLs). The 21 known FA 
proteins act in a linear pathway to repair the ICLs: Following ICL detection, an upstream 
FA core complex monoubiquitinates and activates two central FA pathway members, 
FANCD2 and FANCI, that subsequently orchestrate the recruitment of downstream FA 
proteins to repair the ICL. The molecular mechanisms that allow FANCD2 to promote 
ICL repair are not completely understood, however it was shown that FANCD2 possesses 
a histone H3 chaperone activity that is crucial for cellular ICL resistance. Beyond 
FANCD2’s role in ICL repair, recent findings from our laboratory and others 
demonstrated that FANCD2 functions at hydroxyurea (HU) or aphidicolin (APH) stalled 
DNA replication forks to promote fork restart via homologous recombination 
mechanisms. In this study, we identified a novel FANCD2 interactor named ATRX 
(Alpha Thalassemia Retardation X-linked factor). ATRX is known to function in a 
constitutive complex with DAXX (Death domain associated protein) to act as a histone 
H3.3 chaperone that regulates chromatin structure. Importantly, ATRX – like FANCD2 – 
is known to promote replication fork recovery, hinting at overlapping roles of ATRX and 
FANCD2 during the replication stress response. Our new findings demonstrate that 
ATRX forms a constitutive complex with FANCD2 and promotes FANCD2 protein 
stability. Whereas ATRX is dispensable for the cellular DNA ICL resistance, it works in 
concert with FANCD2 to promote cellular resistance to HU. Moreover, the 
ATRX/DAXX complex cooperates with FANCD2 and the key HR factor MRE11 to 
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promote the restart of HU-stalled replication forks, suggesting that ATRX/DAXX-
mediated histone H3.3 deposition is required for HR mechanisms at stalled replication 
forks. Supporting this idea, ATRX and FANCD2 also cooperate to recruit the HR factor 
CtIP into DNA repair foci following fork stalling. Strikingly, FANCD2’s own histone H3 
chaperone activity is indispensable for replication fork restart as well, indicating that 
histone H3 exchange at stalled replication forks is a crucial step in HR-mediated fork 
restart.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  66 
3.1 Introduction 
Fanconi Anemia (FA) is a recessively inherited genomic instability syndrome 
caused by mutations in any one of twenty one known FA genes (Ceccaldi et al., 2016a; 
Duxin and Walter, 2015; Kee and D’Andrea, 2012; Kupfer, 2013). FA patients exhibit 
congenital abnormalities, progressive bone marrow failure and a strong predisposition to 
cancers such as acute myeloid leukemia and squamous cell carcinomas. Cells from FA 
patients are hypersensitive to DNA interstrand crosslinks (DNA ICLs) and show 
spontaneous chromosomal aberrations that are further exacerbated upon treatment with 
replication-inhibiting agents such as hydroxyurea (HU) or aphidicolin (APH) (Kee and 
D’Andrea, 2010; Naim and Rosselli, 2009; Schlacher et al., 2012). To promote the repair 
of DNA ICLs, the FA pathway members are thought to function in a linear hierarchy that 
can be broadly divided into three tiers: an upstream FA core complex (at least 8 proteins), 
a central FANCD2-FANCI protein heterodimer (named the ID2 complex) and several 
downstream FA pathway members including the Breast Cancer Associated proteins, 
BRCA1/FANCS and BRCA2FANCD1 (Ceccaldi et al., 2016a; Duxin and Walter, 2015; 
Kee and D’Andrea, 2012; Wang, 2007). DNA ICLs are mostly repaired in S-phase when 
they block the progression of replication forks (Clauson et al., 2013; Knipscheer et al., 
2009; Räschle et al., 2008). Detection of an ICL triggers the recruitment of the FA core 
complex, followed by the ID2 complex. The FA core complex then acts as an E3 
ubiquitin ligase that monoubiquitinates both subunits of the ID2 complex (ID2Ub). 
(Garcia-Higuera et al., 2001; Liang et al., 1998; Meetei et al., 2003; Smogorzewska et al., 
2007; Timmers et al., 2001; van Twest et al., 2017). Subsequently, ID2Ub  coordinate the 
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recruitment of downstream FA proteins to promote incisions at the DNA ICL, followed 
by HR-mediated repair of the resulting DNA double strand break (DSB) (Crossan et al., 
2011; Kim et al., 2008b; Klein Douwel et al., 2014; Stoepker et al., 2011; Walden and 
Deans, 2014; Yamamoto et al., 2011). 
Intriguingly, a recent study showed that the recombinant FANCD2 protein can act 
as a histone H3 chaperone that forms a complex with the H3/H4 histone tetramer and 
promotes complete nucleosome assembly in vitro. The authors also showed that cells 
expressing FA-D2 patient-derived FANCD2 missense mutants (FANCD2-R302W and 
FANCD2-L231R) lacking H3 chaperone activity, were as ICL sensitive as FANCD2-
depleted cells (Sato et al., 2012, 2014). Thus, FANCD2’s histone H3 chaperone activity 
is crucial for cellular DNA ICL resistance and may be required for other cellular 
functions of FANCD2 as well. 
  Recent studies from our laboratory and others revealed a novel dual role for 
FANCD2 at HU- or APH- stalled DNA replication forks: first, FANCD2 protects nascent 
DNA strands at stalled replication forks from nucleolytic degradation (Chaudhury et al., 
2013; Schlacher et al., 2011, 2012; Ying et al., 2012). Second, FANCD2 acts in concert 
with several HR factors to promote the restart of the stalled replication forks, which 
simultaneously suppresses the firing of new replication origins (Chaudhury et al., 2014; 
Raghunandan et al., 2015a; Yeo et al., 2014).  
To gain a better understanding of how FANCD2 may function during the S-phase 
replication stress response, we performed mass spectrometry analysis of FANCD2 
interacting proteins and identified a novel FANCD2-associated protein named Alpha 
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Thalassemia Retardation X-linked factor (ATRX). ATRX belongs to the Switch 2, 
Sucrose Non- Fermenting 2 (SWI2/SNF2) family of helicases/ATPases that are known to 
have chromatin modifying roles. Hereditary mutations in ATRX induce a complex 
neurological syndrome (ATRX syndrome) characterized by skeletal deformities, 
distinctive craniofacial features, genital anomalies, severe developmental delays, 
intellectual disability and alpha-thalassemia (Gibbons et al., 1995, 2003; Stevenson, 
1993).  ATRX forms a constitutive complex with DAXX (Death domain associated 
protein), which acts as a specific chaperone for the histone H3 variant, H3.3. The 
ATRX/DAXX complex is known to deposit H3.3 at repetitive DNA sequence regions 
such as the telomeric, pericentric and ribosomal DNA sequence repeats to promote 
heterochromatin formation (Drané et al., 2010; Elsässer et al., 2012; Goldberg et al., 
2010; Lewis et al., 2010; Wong et al., 2010). Recently, ATRX and DAXX were 
identified, quite unexpectedly, to function during the HU-induced replication stress 
response, similar to FANCD2: Following replication fork stalling, ATRX and DAXX 
protect the stalled forks from nucleolytic degradation; moreover, ATRX was shown to 
promote the restart of these stalled forks (Clynes et al., 2014; Huh et al., 2016; Leung et 
al., 2013). 
Here, we asked if FANCD2 and the ATRX/DAXX complex act in concert during 
the replication stress response in S-phase. To this end, we utilized a combination of 
rAAV and CRISPR/Cas9 gene targeting technologies to generate isogenic FANCD2-, 
ATRX-and FANCD2/ATRX double knockout cell lines in an HCT116 cell background. 
A functional characterization of our cell lines revealed that ATRX forms a constitutive 
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complex with FANCD2 and stabilizes FANCD2 protein levels. Importantly, ATRX is not 
required for the FANCD2-dependent cellular DNA ICL resistance. In contrast, ATRX 
and FANCD2 cooperate with the homologous recombination (HR) factor MRE11 to 
promote replication fork restart. ATRX and FANCD2 also cooperate to recruit the HR 
factor CtIP to chromatin following replication fork stalling, indicating that ATRX has a 
new role in promoting FANCD2- dependent HR mechanisms. Lastly, we find that both 
the histone H3.3 depositor DAXX, as well as the histone H3 chaperone function of 
FANCD2, are required for replication fork restart. Our findings implicate that a 
functional protein complex containing ATRX/DAXX, FANCD2 and MRE11 utilizes 
histone H3 variant chaperone activities to promote the HR-driven restart of stalled 
replication forks. 
3.2 Results  
FANCD2 interacts with ATRX to form a constitutive protein complex in the presence 
or absence of DNA damage 
To better understand S-phase specific functions of FANCD2 we set out to identify 
novel, S-phase specific interactors of FANCD2. To this end, we performed pulldown 
studies from S-phase Xenopus laevis S-phase egg extracts that are stockpiled with DNA 
replication and repair proteins and allow for the detection of even less abundant protein 
complexes. We used a Xenopus laevis FANCD2 (xFANCD2) specific antibody (Sobeck 
et al., 2006) to pull down xFANCD2 from high-speed S-phase egg extracts (Sobeck et al., 
2006, 2007), followed by mass spectrometric identification of the xFANCD2-associated 
proteins (a detailed description of the procedure and the analysis of the identified 
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FANCD2 protein interactors will be published elsewhere). One of the proteins identified 
by our mass spectrometry screen was ATRX. Interestingly, the human ATRX and 
FANCD2 proteins share a known interactor, the MRN (MRE11-NBS1-RAD50) complex 
(Clynes et al., 2014; Leung et al., 2013; Roques and Masson, 2010; Roques et al., 2009). 
In fact, it was previously shown that MRE11 interacts with FANCD2 in human cells to 
protect FANCD2 from proteosomal degradation (Roques et al., 2009). To identify if 
ATRX and FANCD2 have a comparable relationship, we immunoprecipitated (IP-ed) 
FANCD2 from human wild type cells (PD20+3xFLAG-FANCD2; an FA-D2 patient-
derived cell line complemented with triple FLAG-tagged wild type FANCD2).  As 
shown in Fig. 3.1A, an anti-FLAG antibody) co-immunoprecipitated (co-IPed) ATRX 
with FANCD2. In the reciprocal experiment, we successfully co-IPed FANCD2 with an 
anti-ATRX antibody from the same wild type cells (Fig. 3.1B). Of note, we performed 
this experiment in the presence of the DNase Benzonase and the DNA intercalator 
ethidium bromide, indicating that the ATRX-FANCD2 interaction is not mediated by 
DNA. To test whether the ATRX-FANCD2 interaction was improved following DNA 
damage, we IP-ed ATRX from wild type cells that were either untreated or treated with 
HU. We observed that DNA damage did not significantly alter the degree of interaction 
between FANCD2 and ATRX (Fig. 3.1B, lanes 4 and 5). As previously described, we 
were also able to co-IP the MRN complex member, NBS1, with both ATRX and 
FANCD2 (Fig. 3.1C). These findings indicate that ATRX, FANCD2 and MRN 
participate in a constitutive protein complex that forms independently of the presence or 
absence of DNA damage.  
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Figure 3.1 
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Figure 3.1: FANCD2 interacts with ATRX.  
All IP experiments were performed from nuclear extracts (NE) prepared from PD20 + 3x FLAG-
FANCD2 cells, in the presence of Benzonase and EtBr. (A) ATRX co-IPs with FANCD2. NEs 
were subjected to IP with mouse IgG (lane 2; neg. control) or the anti-FLAG antibody (lane 3). 
NE and IP samples were analyzed for the presence of FANCD2 and ATRX by western blot. (B) 
FANCD2 co-IPs with ATRX. NE were either treated without or with 2mM HU for 24h (lanes 1 
and 2) and subjected to IP with rabbit IgG (lane 3; neg. control) or the anti-ATRX antibody (lanes 
4 and 5). (C) NBS1 co-IPs with ATRX and FANCD2. NEs were subjected to IP with: left panel- 
rabbit IgG (lane 2; neg. control) or the anti-ATRX antibody (lane 3); right panel- mouse IgG 
(lane 2; neg. control) or the anti-FLAG antibody (lanes 3). 
ATRX promotes FANCD2 protein stability. (D) Whole cell extract (WCEs) were prepared from 
human PD20+D2 cells that had been treated with control siRNA (siControl- lanes 1 and 3) or 
ATRX siRNA (siATRX#1- lanes 2 and 4) for the indicated time points and analyzed for ATRX 
and FANCD2. Ku-86 loading control. (E) WCEs were prepared from human hTERT-RPE cells 
that had been treated with control siRNA (siControl- lanes 1 and 3) or ATRX siRNA (siATRX#1- 
lanes 2 and 4) for 72 hours. At 67 hours, these cells were treated with either DMSO (lanes 1 and 
2) or MG132 (10uM for 5 hours- lanes 3 and 4). WCEs was analyzed for ATRX and FANCD2. 
Ku-86 loading control, Cyclin B- positive control for MG132 activity.  (F) Same as (E), but using 
a second siRNA against ATRX- siATRX#2. At 67 hours, these cells were treated with either 
DMSO (lanes 1 and 3) or MG132 (10uM for 5 hours- lanes 2 and 4). WCEs were analyzed for 
ATRX and FANCD2. Ku-86: loading control, Cyclin B: positive control for MG132 activity.  
For D-F, immunoblot signals for FANCD2 were analyzed by densitometry and normalized 
against Ku-86 signals using ImageJ. The normalized values are provided under the corresponding 
lanes below the FANCD2 blot in each figure 
 
To test if ATRX – like MRE11 – stabilizes FANCD2 protein levels, we treated 
wild type cells (PD20+ FANCD2) with either control siRNA or an siRNA against ATRX 
(siATRX#1) for 48 hr or 72 hr. An analysis of ATRX and FANCD2 protein levels 
revealed that FANCD2 protein levels were significantly reduced in ATRX-depleted cells, 
compared to the control cells.  (Fig 3.1D). We confirmed these findings in a second cell 
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line, RPE1 (Retinal Pigment Epithelium-1). Similar to the siRNA-mediated ATRX 
knockdown in PD20+ FANCD2 cells (Fig. 3.1 D), ATRX knockdown with two different 
siRNAs (ATRX#1 and ATRX #2) caused a reduction of FANCD2 protein levels in RPE1 
cells (Fig 3.1E, compare lanes 1 and 2; Fig. 3.1F, compare lanes 1 and 3). Importantly, 
treatment with the proteasome inhibitor, MG132, restored the FANCD2 protein levels in 
ATRX-depleted RPE1 cells (Fig 3.1E, compare lanes 3 and 4; Fig. 3.1F, compare lanes 2 
and 4). Thus, ATRX interacts with and stabilizes FANCD2 protein molecules, protecting 
them from proteasomal degradation. 
Generation of human isogenic FANCD2-/-, ATRX-/o and FANCD2/ATRX-/-cell lines 
To determine the functional interactions between FANCD2 and ATRX, we set out 
to generate isogenic FANCD2, ATRX and FANCD2/ATRX knockout (KO) cells using 
HCT116 as the parental cell line. To this end, we used a combination of CRISPR/Cas9 
and rAAV (recombinant adeno-associated virus)-mediated gene targeting techniques. To 
create the FANCD2 KO (D2-/-) cell line (Thompson & Yeo et. al, 2017, submitted) we 
targeted the FANCD2 exon 12. For the first round of targeting, conditional rAAV vectors 
that contained LoxP sites flanking both a NEO gene and the targeted exon were designed. 
An additional straight knockout vector to replace exon 12 with a NEO gene flanked by 
LoxP sites was also designed for FANCD2. The D2-/- cell line was generated using two 
rounds of rAAV gene targeting, first with the conditional vector and second with the 
knockout vector. Cre recombinase was subsequently used to remove the NEO gene and 
the conditional allele (Fig. 3.2A). To generate the ATRX KO cell line, a guide RNA was 
designed to target the Cas9 endonuclease to cleave within an endogenous restriction 
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enzyme (SmlI) recognition site in ATRX exon 9 as described previously. ATRX, being an 
X-linked gene, is mono-allelic in the male HCT116 cells line (Napier et al., 2015) (Fig. 
3.2B). To generate the FANCD2/ATRX KO (D2AX-/-) cell line, the same CRISPR/Cas9 
gene targeting system was used to knock out ATRX in the D2-/- cells. For the generation 
of the ATRX-/o and D2AX-/- cell lines, we screened the genomic DNA of the targeted 
clones for the ones with complete resistance to digestion with SmlI within ATRX exon 9, 
indicating disruption of ATRX (Fig. 3.2B and C). Sequence analysis of the targeted 
region was used to confirm that the D2AX-/- clone had CRISPR/Cas9-induced frameshift 
mutations in ATRX. Western blot analysis of whole cell extracts (WCEs) prepared from 
WT, D2-/-, ATRX-/o and D2AX-/- cells confirmed that the genetically null cells lacked 
protein expression of FANCD2, ATRX, or both. (Fig. 3.2D). 
In agreement with our ATRX knockdown experiments described above, we found 
that the ATRX-/o cells contained reduced FANCD2 protein expression levels compared to 
the WT cells independently of the presence or absence of HU-induced DNA damage 
(Fig. 3.2D, compare lanes 1 with 3 and 5 with 7). In contrast, ATRX protein levels 
remained unchanged in D2-/- cells compared to WT cells, demonstrating that ATRX does 
not rely on FANCD2 for its own protein stability.  Despite the reduced overall FANCD2 
protein levels in ATRX-/o cells, FANCD2ub formation following HU treatment was 
robustly and equally induced in WT and ATRX-/o cells, indicating that FANCD2 
monoubiquitination occurs independently of ATRX (Fig. 3.2D, compare lanes 5 and 7).  
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Figure 3.2 
 
 
Figure 3.2: Generation of somatic genetic knock out cell lines for FANCD2, ATRX and 
FANCD2/ATRX.  
(A) D2-/- cell line generation: rAAV (recombinant adeno-associated virus)-mediated gene 
targeting was used to knock out FANCD2 from HCT116 cells. The first round of targeting with 
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the conditional vector replaced FANCD2 exon 12 with a conditional, floxed allele along with a 
Neo selection cassette, also flanked by LoxP sites. G418 resistant clones were screened by PCR 
to confirm targeting, and Cre recombinase was used to remove the Neo selection cassette. The 
FANCD2 second round of targeting was performed in the D2flox/+ cells with the knock-out rAAV 
vector to replace exon 12 with a Neo selection cassette. Cre recombinase was used to remove 
both the Neo selection cassette and the conditional allele(s) resulting in viable D2-/- clones. (B) 
ATRX-/o cell line generation. Following single cell cloning of HCT116 cells co-transfected with 
CRISPR/Cas9 correctly targeted clones were identified by restriction enzyme analysis of a PCR 
product that encompassed the CRISPR target (Figure 1A). HCT116 clones with a disrupted 
ATRX gene were resistant to digestion with the SmlI restriction enzyme due to removal of the 
SmlI recognition site, which was verified by Sanger sequencing. Clone #94 was used in 
subsequent experiments. (C) D2AX-/-cell line generation. The CRISPR described in (B) was 
transfected in the D2-/- cells generated from (A). D2-/- clones with a disrupted ATRX gene were 
resistant to digestion with the SmlI restriction enzyme due to removal of the SmlI recognition 
site, which was verified by Sanger sequencing. Clone #6.9 was used in subsequent experiments. 
(D) WCEs were prepared from HCT116- WT, D2-/-, ATRX-/o or D2AX-/- cells. All four cell lines 
were untreated (lanes 1-4) or treated with 2mM HU for 24 h (lanes 5-8) and analyzed for the 
presence of FANCD2 and ATRX by western blot. Tubulin: loading control. (E) FANCD2-, 
ATRX- or FANCD2/ATRX- deficiency results in cellular proliferation defects. Proliferation 
rates for WT, D2-/-, ATRX-/o and D2AX-/- cells were compared over five days using MTS assay. 
The values are shown as absorbance readings at 595 nm, after treatment with the MTS reagent. 
 
FANCD2 and ATRX can contribute separately to cell proliferation 
Previous studies suggested that FANCD2 supports normal cell proliferation (Thomposon 
and Yeo et. al., submitted, Houghtaling et al., 2003). Similarly, ATRX was previously 
shown to contribute to cellular proliferation as well (Bérubé et al., 2005; Huh et al., 2012; 
Watson et al., 2013). To test if FANCD2 and ATRX cooperate to promote cell 
proliferation, we analyzed the cellular growth of WT, D2-/-, ATRX-/o and D2AX-/- cells 
using an MTS assay. The three knockout cell lines exhibited significantly reduced 
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cellular growth rates compared to the WT cells, indicating that FANCD2 and ATRX both 
contribute to cell proliferation. Strikingly, the cellular growth rates of the three knockout 
cell lines were also significantly different from one another, with decreasing viabilities in 
the following order: ATRX-/o > D2-/- > D2AX-/- cells (Fig. 3.2E). These results indicate 
that FANCD2 and ATRX have partially non-overlapping roles to promote cellular 
proliferation in otherwise unperturbed conditions. 
FANCD2 functions independently of ATRX to mediate ICL repair 
A hallmark of FA is the cellular hypersensitivity to DNA ICL-inducing agents 
such as MMC (Garcia-Higuera et al., 2001; Kee and D’Andrea, 2010). To test if ATRX 
participates in the FANCD2-mediated cellular resistance to DNA ICL agents, we 
performed a colony formation assay.  WT, D2-/-, ATRX-/o and D2AX-/- cells were plated 
and either left untreated or treated with increasing concentrations of MMC. Colony 
formation ability of each cell line was determined after 12-14 days. The D2-/- and   
D2AX-/- cells exhibited a severe hypersensitivity to MMC even at the lowest MMC 
concentration (5nM) compared to WT cells (Fig. 3.3A, D2-/- cells: 15% survival; D2AX-/- 
cells: 17% survival; WT cells: 82% survival). In stark contrast, the ATRX-/o cells did not 
exhibit any MMC sensitivity compared to the WT cells (Fig. 3.3A, ATRX-/o cells, 81% 
survival). These results indicate that ATRX is dispensable for the FANCD2-mediated 
cellular DNA ICL resistance. 
 
 
 
 
  78 
Figure 3.3 
 
Figure 3.3: FANCD2 functions independently of ATRX for ICL resistance, but works in 
concert with ATRX for HU resistance.  
(A) FANCD2 promotes ICL resistance independently of ATRX. WT, D2-/-, ATRX-/o, and 
D2AX-/-  cells were treated with 5, 10 or 15 nM MMC, and assayed for colony forming ability 
after 10 days. (B) FANCD2 acts in concert with ATRX to promote HU resistance. WT, D2-/-, 
ATRX-/o, and D2AX-/-  cells were treated with 50, 10 or 150 µM HU, and assayed for colony 
forming ability after 10 days. 
For both (A) & (B), only colonies containing more than 50 cells were considered. The 
percentage of colony forming cells was normalized to the plating efficiency of the respective 
cell line in untreated conditions as 100% survival. 
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FANCD2 and ATRX act in concert to promote cellular resistance to HU 
Recent findings from Chen et. al., 2016 shows that FANCD2 promotes cellular 
resistance to HU-mediated replication stress (Chen et al., 2016). Similarly, ATRX was 
previously reported to promote cellular HU resistance (Clynes et al., 2014; Leung et al., 
2013). To test if ATRX and FANCD2 act in concert to perform this function, WT, D2-/-, 
ATRX-/o and D2AX-/- cells were plated and left either untreated or treated with increasing 
concentrations of HU. Colony formation of each cell line was determined after 12-14 
days. Strikingly, we observed that the D2-/-, ATRX-/o and D2AX-/- cells were all 
considerably and equally sensitive to HU compared to the WT cells (Fig. 3.3B, 150uM 
HU: WT cells, 80% survival; D2-/- cells, 41.7% survival; ATRX-/o cells, 52.6 % survival; 
D2AX-/- cells, 45.4% survival). Thus, FANCD2 and ATRX act within the same pathway 
to mediate cellular HU resistance.  
ATRX cooperates with FANCD2 to promote replication fork restart. 
 Previous findings from our laboratory showed that FANCD2 functions to mediate 
the restart of APH-stalled replication forks (Chaudhury et al., 2013; Raghunandan et al., 
2015a; Yeo et al., 2014). Similarly, studies from other laboratories showed that ATRX 
promotes the restart of HU-stalled replication forks (Clynes et al., 2014; Leung et al., 
2013). Thus, we asked if FANCD2 and ATRX act in concert to fulfill this role. We 
monitored the replication events in WT, D2-/-, ATRX-/- and AXD2-/- cells using a dual-
labeling DNA fiber assay, as described before (Chaudhury et al., 2013; Davies et al., 
2007; Raghunandan et al., 2015a). Replication tracts were first labeled with DigU (red 
label) for 25 min, then either kept untreated or treated with HU for 5h to cause replication 
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fork arrest, followed by second labeling with EdU (green label) for 40 min. We found 
that compared to the WT cells, the proportion of replication forks competent for restart 
was reduced significantly and equally in D2-/- and ATRX-/- cells (Fig.3.4A, WT cells: 
84.4%; D2-/- cells: 37.6%; ATRX-/- cells: 41.6%). In parallel, the proportion of newly 
originated replication tracts increased significantly and equally (Fig. 3.4B, ∼2-fold) in 
D2-/- and ATRX-/- cells compared to the WT cells. Somewhat unexpectedly, the D2AX-/- 
cells – compared to the D2-/- cells - showed a milder defect in replication fork restart (Fig. 
3.4A, AXD2-/-: 48.2%), accompanied by a moderate, but significant increase in the 
proportion of newly originated replication tracts (Fig. 3.4B, 1.5 fold). To confirm these 
results in a different genetic background, we repeated our experiments in FA-D2-
deficient patient fibroblasts (PD20) that were complemented with either empty vector or 
wild type FANCD2 (PD20+FANCD2WT). To generate WT, FANCD2-deficient, ATRX-
deficient and FANCD2/ATRX-double deficient cells, we treated the PD20+FANCD2WT 
or PD20 cells with either control siRNA or ATRX siRNA, followed by the dual-label 
DNA fiber analysis. In agreement with our findings in the knockout cell lines, we found 
that compared to the WT cells, the proportion of replication forks competent for restart 
was reduced significantly and equally in FANCD2-deficient and ATRX-deficient 
(Fig.3.4C, WT: 82.4%; FANCD2-deficient: 40%; ATRX-deficient: 40.67%), 
accompanied with a similar increase in the number of newly fired replication origins that 
fire (Fig. 3.4, ~3 fold). Similar to D2AX-/- cells, FANCD2/ATRX-double deficient cells 
compared to the FANCD2-deficient cells - showed a milder defect in replication fork 
restart (Fig. 3.4A, FANCD2/ATRX-double deficient: 56.6%), accompanied by a 
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moderate increase in the proportion of newly originated replication tracts (Fig. 3.4B, 2.5 
fold). 
Figure 3.4 
 
Figure 3.4: FANCD2 cooperates with ATRX to mediate replication fork restart  
(A-B) FANCD2- and ATRX- null cells show replication restart defects after HU 
treatment. (A) Replication fork restart efficiencies were compared between WT, D2-/-, 
ATRX-/o, and D2AX-/-  cells. (B) The number of new sites of replication originating during 
the 40 min recovery period after HU treatment was compared between WT, D2-/-, ATRX-/o, 
and D2AX-/-  cells. (C-D) Generated cell types: Wild type (PD20+FANCD2, siControl), 
FANCD2-deficient (PD20, siControl), ATRX-deficient (PD20+FANCD2, siATRX) and 
FANCD2/ATRX double-deficient (PD20, siATRX). FANCD2- and ATRX- deficient 
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cells show replication restart defects after HU treatment. (C)Replication fork restart 
efficiencies after HU treatment were compared between the four cell types described. (D) 
The number of new replication sites originating during EdU labeling after HU treatment was 
compared between the four cell types described in (C) 
NOTE (for all DNA fiber assays): Replication tracts are first labeled with DigU label for 25 
min, treated without or with 4 mM HU for 5 hours to cause replication fork arrest, followed 
by a second labeling with EdU label for 40 min. Replication restart efficiency was measured 
as the number of restarted replication forks after APH-mediated fork stalling (DigU-EdU 
tracts), compared with the total number of DigU-labeled tracts (DigU + DigU-EdU). New 
origins of replication were measured as the number of EdU-only tracts per unit length. 
  
These results indicate that FANCD2 and ATRX cooperate to promote the restart 
of HU-stalled replication forks and suppressing firing of new origins. Moreover, they 
indicate that cells doubly deficient for FANCD2 and ATRX may activate an alternative 
path towards replication fork restart. 
The ATRX-interactor DAXX cooperates with FANCD2 to promote replication fork 
restart. 
ATRX forms a constitutive complex with DAXX to act as a histone H3.3 
chaperone (Drané et al., 2010; Lewis et al., 2010). We asked if DAXX – like ATRX – 
promotes the FANCD2-dependent restart of HU-stalled replication forks. To generate 
wild type, FANCD2-, DAXX-, or FANCD2/DAXX double-deficient cells, we treated 
PD20+ FANCD2WT or PD20 cells with control siRNA or DAXX siRNA (Figure 3.5A). 
DNA fiber analysis after HU mediated replication fork stalling revealed that compared to 
the WT cells, the proportion of replication forks competent for restart was reduced 
significantly and equally in FANCD2-deficient and DAXX-deficient cells (Fig 3.5B, 
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WT: 82.1%; FANCD2-deficient: 44.8%; DAXX-deficient: 38.1%), accompanied with a 
similar increase in the number of newly fired replication origins (Fig.3.4, ~3 fold). 
Similar to D2AX-/- cells, FANCD2/ATRX-double deficient cells compared to the 
FANCD2-deficient cells - showed a milder defect in replication fork restart (Fig. 3.4A, 
FANCD2/ATRX-double deficient: 56.6%), accompanied by a moderate, but significant 
increase in the proportion of newly originated replication tracts (Fig. 3.5B and C, new 
origin firing, 1.5 fold). These results indicate that both subunits of the ATRX/DAXX 
complex cooperate with FANCD2 to mediate the restart of HU-stalled replication forks 
while suppressing the firing of new origins. This in turn suggests that the histone H3.3 
deposition function of the ATRX/DAXX complex may be crucial for replication fork 
restart. Moreover, these results support a model where a cellular deficiency in both 
FANCD2 and the ATRX/DAXX complex triggers a backup path towards replication fork 
restart. 
 
 
 
 
 
 
 
 
 
  84 
Figure 3.5 
 
 
Figure 3.5: FANCD2 cooperates with H3.3 chaperone DAXX to mediate replication fork 
restart 
 (A) WCEs showing the efficiency of siRNA-mediated DAXX knockdown in FANCD2-
proficient or -deficient cells. Generated cell types: Wild type (PD20+FANCD2, siControl), 
FANCD2-deficient (PD20, siControl), DAXX-deficient (PD20+FANCD2, siDAXX) and 
FANCD2/DAXX double-deficient (PD20, siDAXX). Ku-86, loading control. (B-C) FANCD2- 
and DAXX- deficient cells shows replication restart defects after HU treatment. (B) 
Replication fork restart efficiencies after HU treatment were compared between the four cell 
types described in (A). (C) The number of new replication sites originating during EdU labeling 
after HU treatment was compared between the four cell types described in (A). 
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Histone chaperone activity of the non-ubiquitinated FANCD2 isoform is required to 
mediate replication fork restart. 
Previous studies showed that FANCD2 has histone H3 chaperone activity, albeit 
it remains unclear, which of the histone H3 variants is actually deposited by FANCD2. 
These studies also showed that FANCD2’s histone chaperone activity is required to 
promote cellular resistance to DNA ICLs. Inspired by our findings above suggesting that 
replication fork restart requires the ATRX/DAXX histone H3.3 chaperone activity (Fig 
3.5), we asked if FANCD2’s own histone chaperone activity is also required for 
mediating the restart of HU-stalled replication forks. We took advantage of a recently 
described patient-derived FANCD2 missense mutant, FANCD2L231R, that lacks histone 
H3 deposition activity (Sato et al., 2012, 2014). We reconstituted the D2-/- cells with 
FANCD2WT or FANCD2L231R (Fig 3.6A). Importantly, since FANCD2L231R is known to 
exhibit reduced chromatin binding activity (Sato et al., 2014), we first compared 
FANCD2 chromatin binding of cells that expressed normal, WT-like levels of 
FANCD2L231R (D2-/- + FANCD2L231R_NOR) or cells that overexpressed FANCD2L231R (D2-
/- + FANCD2L231R_HI) to that of cells reconstituted with the WT FANCD2 (D2-/- + 
FANCD2WT). Compared to the D2-/-+ FANCD2WT cells, D2-/- + FANCD2L231R_NOR 
showed a significantly reduced chromatin binding. However, the overexpression of the 
mutant protein in the D2-/- + FANCD2L231R_HI cells was able to compensate for the 
weaker chromatin affinity of the FANCD2L231R, resulting in equal chromatin recruitment 
compared to the FANCD2WT protein. 
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To test whether FANCD2’s histone chaperone activity promotes replication fork 
restart, we performed the DNA fiber assay using WT cells and D2-/- cells complimented 
with either empty vector, FANCD2WT or FANCD2L231R_HI. In agreement with our 
previous findings, the D2-/- cells show a significant reduction in replication fork restart 
efficiency after HU treatment (Fig. 3.6C, D2-/-: 49.3%). This defect was relieved in D2-/- 
cells expressing FANCD2WT (Fig. 3.6C, D2-/- + FANCD2WT: 78.8%), but not in cells 
expressing the FANCD2L231R_HI mutant (Fig. 3.6C, D2-/- + FANCD2L231R: 54.4%). 
Simultaneously, the significant increase in new origin firing observed in D2-/- cells (Fig. 
3.6D; ~2-fold increase compared to D2-/- + FANCD2WT) was suppressed in the D2-/- + 
FANCD2WT cells, but not in the D2-/- + FANCD2L231R_HI cells (Fig. 3.6D; ~2-fold 
increase compared to D2-/- + FANCD2WT).  
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Figure 3.6 
 
 
 
Figure 3.6: FANCD2’s histone H3 chaperone activity is required to mediate replication fork 
restart  
(A) WCEs extracts examining FANCD2 levels in the following HCT116 derived cell 
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lines: WT or D2-/- cells complemented with either FANCD2WT (clone # 3, 18 20; lanes 2-
4) or the histone chaperone dead mutant FANCD2L231R (clone # 5, 7, 8; lanes 6-8). 
Tubulin-loading control. (B) D2-/- cells complimented with either FANCD2WT (lanes 1-2) 
or FANCD2L231R mutant (FANCD2L231R_NOR, lanes 3-4; FANCD2L231R_HI, lanes 5-6); and 
L-/- cells (lanes 7-8) were either untreated or treated with HU, and chromatin fractions 
from the cells were analyzed for the presence of FANCD2. TFIIH: loading control. (C 
and D) FANCD2L231R_HI shows replication restart defects after HU treatment. 
(C)Replication fork restart efficiencies after HU treatment were compared between WT, 
L-/-, or D2-/- cells complemented with empty vector, FAND2WT or FANCD2L231R_HI. (D) 
The number of new replication sites originating during EdU labeling after HU treatment 
was compared between the four cell types described in (C). 
 
It was previously shown that the FANCD2L231R mutant protein cannot get 
monoubiquitinated (Sato et al., 2014), raising the possibility that it is this modification 
defect that blocks the FANCD2L231R mutant from promoting fork recovery. However we 
previously presented evidence that monoubiquitination of FANCD2 is not required for 
replication fork restart (Raghunandan et al., 2015). In agreement with these findings, we 
observed that HCT116 cells deficient in the FA core complex E3 ubiquitin ligase subunit, 
FANCL (L-/- cells) were completely proficient for replication fork restart (Fig3.6B, L-/-: 
78.6%), and the suppression of new origin firing (Figure 3.6C, L-/-: 0.8-fold) in the same 
experiment. Notably, the L -/- cells exhibited significantly less chromatin-bound WT 
FANCD2 than the D2-/-+ FANCD2L231R_HI cells (Fig. 3.6B, compare lanes 2 and 3, or 5 
and 6). Thus, although the nonubiquitinated FANCD2L231R_HI has a higher chromatin 
binding capability than the nonubiquitinated WT FANCD2 in L-/-  cells, it fails to 
promote replication fork restart. We conclude that the histone H3 chaperone activity of 
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FANCD2, and not FANCD2 monoubiquitination, is required to mediate the restart of 
stalled replication forks.  
FANCD2 and ATRX cooperate with MRE11 to promote replication fork restart.  
Both FANCD2 and ATRX have been independently shown to interact with the 
MRE11 nuclease (Clynes et al., 2014; Leung et al., 2013; Roques et al., 2009). Moreover, 
it is known that MRE11 is one of many HR factors that are required to promote 
replication fork restart (Bryant et al., 2009; Raghunandan et al., 2015b; Somyajit et al., 
2015; Yeo et al., 2014). To test if ATRX and FANCD2 work in concert with MRE11 to 
promote HR-mediated fork recovery, we made use of a small molecule inhibitor of the 
MRE11 exonuclease activity, mirin, which completely blocks MRE11’s ability to 
promote fork restart (Chaudhury et al., 2014). WT, D2-/-, ATRX-/o and AXD2-/- cells were 
either untreated or pre-incubated with 50µM mirin for one hour. The cells were 
subsequently treated with 4 mM HU for 5 hours and subjected to DNA fiber analysis. As 
expected, mirin-treated WT cells were unable to restart HU-stalled replication forks, 
compared to the untreated WT cells (Chaudhury et al., 2014).  
 
 
 
 
 
 
 
  90 
Figure 3.7 
 
Figure 3.7: FANCD2 and ATRX cooperate with MRE11 to promote replication fork restart 
 (A) Replication fork restart efficiencies were compared between WT, D2-/-, ATRX-/o, and D2AX-
/-  cells after HU treatment. Cells were either untreated or pre-incubated with 50µM mirin for one 
hour. For mirin treated samples all subsequent steps for the DNA fiber assay were carried out in 
the presence of mirin.  (B) The number of new sites of replication originating during the 40 min 
recovery period after HU treatment was compared between WT, D2-/-, ATRX-/o, and D2AX-/-  
cells.  
 
As expected based on our findings above (Fig 3.4A), the D2-/-, ATRX-/o and 
D2AX-/-  cells showed a significant reduction in their replication restart efficiency after 
HU treatment (Fig 3.7A WT: 76.5%; D2-/-: 36.7%; ATRX-/o: 37.6%, D2AX-/-: 51.9%). 
Strikingly, this fork restart defect was (a) not exacerbated upon mirin treatment, and (b) 
comparable to that observed in mirin-treated WT cells (Fig 3.7B WT: 36.25%; D2-/-: 
40.8%; ATRX-/o: 37.9%, D2AX-/-: 48.1%). In parallel, mirin caused an upregulation of 
new origin firing by >2 fold in the HU-treated WT cells, but did not further increase new 
origin firing in the HU-treated D2-/-, ATRX-/o and D2AX-/- cells. These results suggest 
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that the protein complex composed of FANCD2, ATRX/DAXX and MRE11 acts as a 
functional entity to mediate the HR-dependent restart of stalled replication forks. 
FANCD2 and ATRX cooperate to recruit the HR factor CtIP to stalled replication 
forks  
We previously showed that FANCD2 recruits CtIP to chromatin and into HU-
induced DNA repair foci at stalled replication forks (Buis et al., 2012; Yeo et al., 2014). 
To test if ATRX cooperates with FANCD2 to promote CtIP chromatin recruitment, we 
analyzed CtIP foci formation in untreated or HU-treated WT, D2-/-, ATRX-/o and D2AX-/- 
cells. As expected, the WT cells showed an increase in HU-triggered CtIP foci formation 
(Fig 3.8A, cells with >5 CtIP foci, untreated: 10%, HU-treated: 56.3%).  In contrast, the 
D2-/- cells showed severely reduced CtIP foci formation in HU-treated conditions 
(Fig.3.8A (HU) WT cells: 56.3%, D2-/-cells: 3.5%). Importantly, the ATRX-/o cells 
showed a slightly less severe yet highly significant defect in CtIP foci formation (Fig. 
3.10A, (HU) ATRX-/o: 15.2%). Moreover, the D2AX-/- cells closely mirrored the CtIP 
foci formation defect seen in the D2-/- cells (Fig. 3.8A, D2AX-/-cells: 4.1%), suggesting 
that FANCD2 and ATRX act in concert to recruit CtIP to sites of stalled replication forks. 
We attempted to confirm our finding in an independently generated ATRX null cell line 
(rAAVATRX-/o) that was generated using rAAV-mediated gene targeting as previously 
described (Napier et al., 2015). The rAAVATRX-/o cells showed a severe defect in HU-
triggered CtIP foci formation, similar to the ATRX-/- cells described above. (Fig. 3.8B, 
(HU) WT: 50%, rAAVATRX-/o: 20%).  These finding suggest that both ATRX and 
FANCD2 are required to recruit CtIP to sites of stalled replication forks, likely to 
promote HR-mediated restart events. 
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Figure 3.8 
 
Figure 3.8: FANCD2 and ATRX cooperate to recruit CtIP to sites of prolonged HU damage 
to promote HR 
(A) ATRX and FANCD2 cooperate for CtIP foci formation WT, D2-/-, ATRX-/o, and D2AX-/- 
cells were either untreated or treated with 2mM HU for 20 hours. Nuclear CtIP foci formation 
was analyzed by fluorescence microscopy. CtIP foci formation was quantified for distribution 
into % of nuclei with 0-5, 5-10 or >10 foci per nucleus. (B) CtIP depends on ATRX for foci 
formation. WT and rAAVATRX-/o cells were untreated or treated with 2mM HU for 20 hours. 
Nuclei with > 5 foci were considered positive for CtIP foci formation. 
 
The finding that ATRX cooperated with FANCD2 to promote HU-induced CtIP foci 
formation, combined with our earlier observation that ATRX stabilizes FANCD2 protein 
levels, led us to speculate that ATRX may in fact regulate FANCD2’s own recruitment 
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into HU-induced chromatin foci. To test this, we compared FANCD2 foci formation in 
untreated and HU-treated WT and ATRX-/o cells. As expected (Castella et al., 2015; 
Garcia-Higuera et al., 2001; Yeo et al., 2014), FANCD2 re-localization into DNA repair 
foci increased significantly post HU treatment in WT cells (Fig 3.8C, cells with >5 
FANCD2 foci UT: 10%, HU: 47%). Interestingly, the ATRX-/o cells showed a mild 
reduction in the HU-triggered FANCD2 foci formation (Fig 3.8C, cells with >5 FANCD2 
foci, WT: 47%, ATRX-/o: 33%), suggesting that re-localization of FANCD2 to HU-
stalled replication forks is partially dependent on ATRX. Next, we asked if FANCD2 
also reciprocally regulates ATRX foci formation following cellular HU treatment. To this 
end, we monitored ATRX foci formation in untreated or HU-treated WT and D2-/- cells. 
Similar to the findings by Leung et. al., 2013, the percentage of WT cells containing 
ATRX foci did not increase significantly after HU treatment (UT: 55%, HU: 62%). 
Intriguingly however, we observed that following HU treatment, the D2-/- cells exhibited 
significantly increased ATRX foci numbers compared to the WT cells (Fig 3.8D, (HU) % 
cells with >10 ATRX foci: WT, 3.09%; D2-/-, 19.9%). We further confirmed these 
findings in a second set of FA patient-derived FANCD2-deficient cells (PD20) and their 
complemented counterpart (PD20+FANCD2WT). We monitored ATRX foci formation in 
untreated or HU-treated FANCD2-proficient and -deficient cells. Similar to our findings 
in the HCT116 D2-/- cells versus WT cells (Fig 3.8D), we found that the PD20 cells 
exhibited a strongly increased HU-induced ATRX foci formation compared to the 
PD20+D2 cells (Fig 3.8E, (HU) % cells with >10 ATRX foci: PD20+FANCD2WT: 1%, 
PD20: 11%). Together, these findings indicate that FANCD2 cooperates with – and 
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partly depends on – ATRX to promote DNA repair at stalled replication forks. 
Furthermore, our data suggest that ATRX accumulates at sites of HU-stalled replication 
forks in FANCD2-deficient cells, possibly in an attempt to compensate for the absence of 
FANCD2 during the cellular HU response. 
Figure 3.9 
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Figure 3.9: FANCD2 and ATRX show altered foci formation in ATRX-/- and D2-/- cells 
respectively 
(A) FANCD2 is partially dependent on ATRX for foci formation. WT and ATRX-/o cells were 
untreated or treated with 2mM HU for 20 hours. Nuclear FANCD2 foci formation was analyzed 
by fluorescence microscopy. (B and C) ATRX accumulates in DNA repair foci in the absence of 
FANCD2. (B) WT and D2-/- cells were untreated or treated with 2mM HU for 20 hours. Nuclear 
ATRX foci formation was analyzed by fluorescence microscopy. (C) Same as (B), in 
PD20+FANCD2WT and PD20 cells. Nuclei positive for FANCD2 and ATRX foci formation 
were quantified for distribution into % of nuclei with 0-5, 5-10 or >10 foci per nucleus. 
 
Discussion 
In this study, we identify a novel physical and functional interaction between 
FANCD2 and the ATRX/DAXX histone H3.3 chaperone complex, using newly 
generated isogenic knockout cell lines. Our results indicate that ATRX/DAXX and 
FANCD2 act in concert to promote the restart of HU-stalled DNA replication forks. 
Moreover, they suggest that this role of ATRX/DAXX and FANCD2 involves a histone 
chaperone activity that is crucial for the recruitment of HR factors to promote fork restart. 
To our knowledge, this is the first study that utilizes human isogenic D2-, ATRX- and 
D2AX double-null cell lines to analyze functional cooperation between the FA and 
ATRX pathways. The successful generation of viable D2-/-, ATRX-/o and D2AX-/- cells 
demonstrates that neither of the two genes are essential in human somatic cells. However, 
this observation does not rule out the possibility that these genes may have important 
roles during normal development; in fact, developmental functions seem likely 
considering the development abnormalities observed in both FA and ATRX patients. 
Though not essential, both FANCD2 and ATRX contribute to cellular proliferation and 
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FANCD2 appears to be more crucial for this feature than ATRX. Importantly, the fact 
that D2AX-/- cells proliferate significantly more slowly than either of the singly null cells 
demonstrates that FANCD2 and ATRX have some partially non-overlapping cellular 
roles. In support of this idea, patients suffering from ATRX or FA syndrome exhibit 
several distinct, non-overlapping phenotypes. For example, ATRX patients present with 
mental retardation and thalassemia, whereas FA patients are clinically characterized by 
bone marrow failure and aplastic anemia. This is further supported by our observation 
that ATRX is completely dispensable for the FANCD2-dependent cellular DNA ICL 
resistance, in agreement with previous studies (Clynes et al., 2014; Leung et al., 2013).  
That said, a literature search revealed that some intriguing phenotypical 
similarities have been described for the ATRX and FA syndromes. Both syndromes are 
associated with congenital skeletal abnormalities including brachydactyly, genital 
anomalies, short stature, epicanthal folds, microcephaly and an increased cancer 
predisposition. (Ceccaldi et al., 2016a; Kalb et al., 2007; Solomon et al., 2013; 
Stevenson, 1993).  
On the cellular level, deficiencies in ATRX or FANCD2 expression have been 
associated with spontaneously elevated levels of chromosome instability that manifest as 
an accumulation of DNA DSBs, increased micronuclei formation and elevated telomere 
fusions (Baumann et al., 2010; Chan et al., 2009; Huh et al., 2012, 2016; Joksic et al., 
2012; Lovejoy et al., 2012; Naim and Rosselli, 2009; Reliene et al., 2010a, 2010b; 
Ritchie et al., 2008; Watson et al., 2013; Wong et al., 2010), hinting that the two proteins 
cooperate to protect genomic stability, thus preventing carcinogenesis. 
  97 
In strong support of this idea, our findings indicate that FANCD2 and ATRX can 
participate in a common protein complex that likely also contains DAXX and the MRE11 
nuclease. It should be pointed out that the interaction between ATRX and FANCD2 
appears to be relatively weak; however, this is typical for all FANCD2 protein 
interactions that have been identified so far. For example, the interactions between 
FANCD2 and BLM, CtIP, FAN1 or even FANCD2’s heterodimerization partner, 
FANCI, have all been shown to be weak and likely rather transient  (Chaudhury et al., 
2013, 2014; Hussain et al., 2004; Murina et al., 2014; Naim and Rosselli, 2009; Pichierri 
et al., 2004; Smogorzewska et al., 2007; Unno et al., 2014; Yeo et al., 2014). In fact, 
protein complex size fractionation experiments from our laboratory (unpublished data)  
and others (Zhi et al., 2010) indicate that FANCD2 can participate in quite a few different 
protein complexes that may additionally only form transiently during S-phase. Somewhat 
puzzlingly, this model is not quite supported by our finding that ATRX prevents 
FANCD2 from proteosomal degradation, which rather suggests that the majority of 
FANCD2 molecules should exist in a robust and constitutive complex with ATRX. 
However, a previous study from the Masson laboratory demonstrated that MRE11- albeit 
not being a strong FANCD2 interactor either – is absolutely crucial to promote FANCD2 
protein stability (Roques et al., 2009). Interestingly MRE11 can interact with both 
FANCD2 and ATRX (Clynes et al., 2014; Leung et al., 2013; Roques et al.,2009), 
hinting that ATRX may only indirectly protect FANCD2 from proteolytic degradation by 
stabilizing the FANCD2-MRE11 interaction.  
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In agreement with the idea of a physical and functional protein complex 
composed of ATRX/DAXX, MRE11 and FANCD2, our findings demonstrate that all 
four proteins act in one pathway to mediate the HR-dependent restart of HU-stalled 
replication forks, which simultaneously suppresses the firing of new replication origins. 
Several additional HR factors are known to promote replication fork restart and recent 
findings from our laboratory showed that several of these factors including CtIP are 
recruited in a FANCD2- and MRE11-dependent manner (Buis et al., 2012; Murina et al., 
2014; Unno et al., 2014; Yeo et al., 2014). Our finding that ATRX works in concert with 
FANCD2 to promote CtIP re-localization to nuclear DNA repair foci, in response to 
cellular HU treatment, strengthens a model where an ATRX/DAXX/MRE11/FANCD2 
protein super-complex assembles in a stepwise manner at stalled replication forks to 
recruit additional HR factors to ultimately promote fork recovery (Fig. 3.10). It is 
interesting in this regard that foci formation for FANCD2 foci appears to be minimally 
affected in absence of ATRX, but for CtIP, depends heavily on ATRX and FANCD2. 
This suggests to us that ATRX and FANCD2 are recruited to sites of stalled replication 
forks largely independently of one another, but then act as a complex to recruit CtIP.  
On the other hand, our finding that HU-induced ATRX foci formation increases 
in D2-/- cells compared to WT cells suggests that ATRX is positioned upstream of 
FANCD2 and ATRX accumulates on chromatin in D2-/- cells in an attempt to partially 
compensate for the absence of FANCD2. A similar relationship has been reported for 
FANCD2 and its downstream target, BRCA2 (Hussain et al., 2004; Wang et al., 2004): 
BRCA2-deficient cells exhibit a large increase in FANCD2 foci formation during DNA 
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ICL repair, presumably because cells are trying to compensate for the absence of 
BRCA2. (Kais et al., 2016).  Future studies will reveal if ATRX is also required for the 
recruitment of other, FANCD2-dependent HR proteins such as BLM, FAN1 or RAD51 
(Chaudhury et al., 2013, 2014; MacKay et al., 2010; Sato et al., 2016). We predict that 
cells deficient in these factors may exhibit an increased HU-triggered ATRX foci 
formation as well. 
The fact that ATRX/DAXX, MRE11 and FANCD2 cooperate to promote HR-
mediated replication fork restart and the recruitment of HR factors following fork 
stalling, strongly suggests that the ATRX/DAXX complex has a hitherto unrecognized 
role in promoting cellular HR mechanisms. This is a highly unexpected finding since the 
current literature suggests that ATRX does in fact act as an inhibitor of HR. This 
prediction is based on findings in ATRX-deficient cancer cells that utilize a different, 
supposedly HR-mediated mechanism of telomere maintenance named ALT (Alternative 
Lengthening of Telomeres) (Dilley and Greenberg, 2015). Based on the correlative 
relationship between ATRX deficiency and hyper-recombinogenic telomeres in ALT 
cells, ATRX has been predicted to be an active suppressor of HR, at least at the 
telomeres. Future studies should reveal whether ATRX fulfills separate functions at non 
telomeric stalled or even collapsed DNA replication forks and at telomeric DNA 
sequences, possibly by associating with different protein complexes at intra-chromosomal 
regions versus the telomeric regions.  
Additional support for a role for ATRX in genome-wide HR repair stems from its 
role as an H3.3 chaperone in complex with DAXX.  A recent study demonstrated that 
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H3.3 deposition at sites of DNA DSBs is crucial for NHEJ and HR-mediated DSB repair, 
indicating that H3.3 variant deposition is generally involved in HR mechanisms 
throughout the genome (Luijsterburg et al., 2016). It is quite intriguing in this context that 
FANCD2 was previously shown to have histone H3 chaperone activity itself, although it 
remains unknown whether FANCD2 has a binding preference for a particular H3 variant 
such as H3.3 (Sato et al., 2012). Nevertheless, based on its cooperative roles with the 
ATRX/DAXX complex during fork recovery, it seems highly plausible that FANCD2 is 
an H3.3-specific chaperone itself. On the other hand, it is possible that FANCD2 has a 
different histone H3 variant specificity that is required – alongside with ATRX/DAXX-
dependent H3.3 deposition – to enable appropriate nucleosome restructuring steps at sites 
of stalled replication forks.  
Remarkably, neither of these two models can account for the perhaps most 
unusual finding of our study, i.e. that the restart of stalled replication forks, while equally 
defective in D2-/- and ATRX-/o cells, became actually more efficient in the D2AX-/- cells. 
While this phenomenon requires future investigations, we would like to point out that we 
did recently observe a somewhat similar phenotype in cells doubly null for FANCD2 and 
FANCI, compared to D2-/- cells. We found that depletion of FANCI significantly 
improved the replication forks restart efficiencies in HU-treated D2-/- cells (Thompson 
and Yeo et. al., 2017, submitted). One possible explanation for this “improved” 
phenotype is that FANCD2 and ATRX both still try to promote the commonly used, 
major HR-mediated fork restart mechanisms, whereas in the absence both proteins, a 
compensatory/back-up pathway is engaged to promote fork recovery. An obvious 
  101 
candidate for this backup would be the NHEJ DNA repair machinery that is upregulated 
in HR-deficient cells (Ceccaldi et al., 2015; Tutt et al., 2001). In fact, NHEJ factors such 
as DNA-PKcs and Ku have been implicated in the replication stress response in recent 
years (Miyoshi et al., 2009; Ying et al., 2016). Additional studies are underway to 
determine which backup pathway is activated to promote replication fork recovery in 
cells lacing both ATRX and FANCD2. 
In summary, we propose a model (Fig. 3.10) wherein the ATRX/DAXX complex 
form a super-complex with MRE11 and FANCD2 at sites of stalled replication forks to 
support a histone H3.3 deposition-dependent, HR-mediated mechanism of replication 
fork restart. 
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Figure 3.10 
 
          
       
 
Figure 3.10: FANCD2 and ATRX promote H3.3 deposition at stalled replication forks and 
promote HR mediated fork restart  
(Text in figure) 
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3.4 Materials and Methods 
Cell lines and cell culture techniques 
FANCD2 deficient (PD20) and complemented cell lines (PD20+FANCD2) were 
obtained from the FA Cell Repository at the Oregon Health & Science University. PD20 
cells complemented with 3xFLAG FANCD2 were a kind gift from Dr. Tosiyashu 
Taniguchi at the Fred Hutchinson Research Centre. All cells described above were 
cultured in DMEM (GIBCO) with 10% FBS and 1% Penicillin-Streptomycin. All 
HCT116 derived cell lines were cultured in Mc Coy's media (Corning) enriched with 
10% FBS, 1% Pencillin-Streptomycin and 1% Glutamine. 
Gene targeting for generating FANCD2-, ATRX- and FANCD2/ATRX- knockouts in 
HCT116 cells. 
rAAV gene targeting mediated generation of FANCD2 - null cells 
FANCD2 null HCT116 cells were generated using rAAV (recombinant adeno-
associated virus)-mediated gene targeting (Kohli et al., 2004).  The detailed method for 
this cell line will be published elsewhere (Thompson and Yeo et. al.). Briefly, conditional 
and knock-out rAAV vectors targeting FANCD2 exon 12 were constructed using Golden 
Gate cloning technology and designed as previously described (Kohli et al., 2004; Oh et 
al., 2014).  The first round of targeting with the conditional vector replaced FANCD2 
exon 12 with conditional, floxed allele along with a floxed Neo selection cassette. G418 
resistant clones were screened by PCR to confirm targeting, and Cre recombinase was 
used to remove the Neo selection cassette.  The FANCD2 second round of targeting was 
performed in the FANCD2flox/+ cells with the knock-out rAAV vector to replace exon 
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12 with a Neo selection cassette. G418 resistant clones were screened by PCR for correct 
targeting.  Cre recombinase was used to remove both the Neo selection cassette and the 
conditional allele(s) and resulted in viable FANCD2-/- clones.   
CRISPR/Cas9 generation of ATRX- and FANCD2/ATRX- null cells 
ATRX-null cells were generated as previously described (Napier et al., 2015). 
The same ATRX guide RNA (gRNA) containing CRISPR/Cas9 plasmid (targeting 
ATRX exon 9) was transfected into the FANCD2- null HCT116 cells using 
Lipofectamine 3000 (Life Technologies).  Two days after transfection the cells were sub-
cloned, and individual sub-clones were screened for targeting by amplification of exon 9 
and subsequent digestion with SmlI (New England BioLabs, Inc.). Sub-clones that were 
resistant to digestion with SmlI were TOPO TA cloned (Life Technologies).  Sanger 
sequencing of the TOPO TA clones confirmed targeted insertion of a single nucleotide, 
that would induce a frameshift in FANCD2, generating a FANCD2/ATRX- null cell line.  
Western blot analysis further confirmed that these clones were null for FANCD2 and 
ATRX expression. The information for ATRX gRNA and the primers used for 
amplification of targeted exon 9 can be found in Napier et. al., 2015. 
The generation of FANCD2 -null cells complemented with FANCD2 is described 
in Thompson and Yeo et. al. Briefly, a human codon optimized FANCD2 cDNA was 
cloned into Piggyback CAG promoter expression vector using Gateway cloning 
technology (Invitrogen). G418 clones were screened for FANCD2 expression by Western 
blot. FANCD2-L231R mutant was generated using site directed mutagenesis kit from 
Stratagene. 
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Immunoprecipitation Assay: 
Nuclear extracts from PD20+3xFLAG FANCD2 cells were generated using a 
protocol generously shared by Dr. Andrew Deans at St. Vincent’s institute of Medical 
research, Australia. Freshly isolated cells were washed in PBS and nuclei were isolated 
using CSK buffer (10 mM PIPES pH6.8, 100 mM NaCl, 300 mM sucrose, 3mM MgCl2, 
0.1% Triton-X100 and complete protease inhibitor). The isolated nuclei were lysed in 
Nuclear lysis buffer (10 mM HEPES pH 7.9, 100 mM NaCl, 1.5mM MgCl2, 25% 
glycerol, 1mM DTT and complete protease inhibitor) using a Dounce homogenizer. The 
nuclear lysates were treated with 50U/ml Benzonase for 1 hour at 4 degrees, with 
rotation. The lysates were spun at maximum speed in table top centrifuge at 4 degrees for 
30 min, twice. The supernatant obtained is the NE used for downstream IP. NE was 
precleared with rabbit or mouse IgG and subjected to immunoprecipitation with anti-
ATRX or anti-FLAG or IgG antibody in presence of EtBr (10 μg/ml) at 4°C overnight. 
Next day, 100ul of Sepharose 4B beads (50% slurry) was added to the NE and rotated for 
30 min at 4°C. The beads were pelleted from solution, washed in nuclear lysis buffer, 
boiled in 1× NuPAGE buffer (Invitrogen) and analyzed by SDS–PAGE and western 
blotting.  
Cell proliferation assay 
Wild type, FANCD2-, ATRX- or FANCD2/ATRX-null cells were plated in 96 
well plates based on their plating efficiencies.  Wild type cells and ATRX-null cells were 
plated at 200 cells/well, FANCD2-null cells were plated at 500 cells/well, 
FANCD2/ATRX-null cells were plated at 1000 cells/well in 96 well plates.   Cell growth 
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was analyzed using MTS assay (Manufacturer’s instructions, Promega) performed in 
triplicate on Days 1, 3 and 5 after seeding. 
MMC and HU sensitivity 
Wild type, FANCD2-, ATRX- or FANCD2/ATRX-null cells were plated in 6 
well plates according to plating efficiency.  Wild type and ATRX- null cells were plated 
at 350 cells/well, FANCD2-null cells were plated at 1000 cells/well, and 
FANCD2/ATRX- null cells were plated at 1200 cells/well in 6-well plates. The next day, 
media removed and media containing 0, 5, 10, and 15 nM MMC OR 0, 50, 100 and 150 
uM HU was added in triplicate to each cell line.  Cells were allowed to grow for 10-12. 
The resulting colonies were then washed in PBS, fixed in 10% Acetic Acid/10% 
methanol, and stained with crystal violet.  Colonies reaching a minimum size of 50 cells 
were counted and normalized to the average colony number in untreated wells. 
Antibodies 
Commercial antibodies were used against human FANCD2 (Santa Cruz, sc-
20022, for WB) (abcam, ab1287- for IFA), ATRX (SC, 15408 for IP and IFA) (Genetex, 
GTX101310- for WB), Ku86 (Santa-Cruz, sc-5280), FLAG (Sigma M2 monoclonal), 
DAXX (sc-7152), Tubulin(XX), Cyclin B(sc-245). Antibodies against CtIP have been 
described previously (Yu X., Baer R. J. Biol. Chem.2000).  
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Immunoblotting 
Protein samples were separated on gradient gels and transferred to Immobilon P 
membranes (Millipore). After blocking in 5% milk, membranes were incubated with 
primary antibodies overnight. Horseradish peroxidase-conjugated rabbit secondary 
antibody (Jackson Labs) or mouse secondary antibody (Biorad) were used at dilutions of 
1:10000 and 1:3000, respectively. Protein bands were visualized using an ECL Plus 
system (Amersham).  
Preparation of whole cell extracts (WCEs) from human cells 
For WCEs preparation, cells were washed in PBS, re-suspended in lysis buffer 
(10mM Tris pH 7.4, 150mM NaCl, 1% NP-40, 0.5% Sodium Deoxycholate, 1mM 
EDTA, 1mM DTT, 0.5mg/ml pefabloc protease inhibitor) and incubated on ice for 20 
min. Cell extracts were centrifuged for 5 min at 10,000 rpm, and the supernatant was 
used for further analysis.  
DNA fiber assay 
We used a previously described DNA fiber protocol (Sugimura K, et al 2007). 
Moving replication forks were labeled with digoxigenin-dUTPs (DigU) for 25 min and 
then with EdU-dUTPs (BioU) for 40 min. To allow efficient incorporation of the DigUs, 
a hypotonic buffer treatment (10 mM HEPES, 30 mM KCl, pH 7.4) preceded the DigU -
labeling step. To visualize labeled fibers, cells were mixed with a 10-fold excess of 
unlabeled cells, fixed and dropped onto slides. After cell lysis, DNA fibers were released 
and extended by tilting the slides. EdU labelled DNA was conjugated to Biotin using 
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Click reaction with Biotin Azide. Incorporated dUTPs were visualized by 
immunofluorescence detection using anti-digoxigenin-Rhodamine (Roche) and 
streptavidin-Alexa-Fluor-488 (Invitrogen). Images were captured using a Deltavision 
microscope (Applied Precision) and analyzed using Deltavision softWoRx 5.5 software. 
All shown DNA fiber results are means of two or three independent experiments (300 
DNA fibers/experiment). Error bars represent the standard error of the mean and 
significance was determined by t-test and Mann-Whitney test. Statistical significance at 
P<0.01, P<0.010, and P<0.0001 are indicated as *, **, ***, respectively. 
siRNA experiments 
siRNA duplexes were purchased from Dharmacon research (Thermo Scientific, 
MA, USA). The sequence of ATRX#1 and ATRX#2 siRNA are 5’ 
GAGGAAACCUUCAAUUGUAUU 3' and 5' GCAGAGAAAUUCCUAAAGAUU 3' 
respectively.  The DAXX siRNA was obtained from Invitrogen (HSS102654). 
siGENOME non-targeting siRNA from Dharmacon was used as a control. Transfections 
were performed using DharmaFECT1 transfection reagent according to the 
manufacturer's protocol. 
Immunofluorescence 
Indirect immunofluorescence was carried out essentially as described (Yeo et al., 
2014). Primary antibodies used: FANCD2 (Abcam, ab2187, 1:4000), CtIP (mouse 
monoclonal, 1:400). Secondary antibodies used: alexa Fluor 594-conjugated goat anti-
rabbit (1:1000) and Alexa Fluor 488-conjugated goat anti-mouse (1:1000; Molecular 
Probes). For statistical analysis of nuclear foci formation, images were taken using a 
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Leica DM LB2 microscope with a Hamamatsu Orca-ER camera. Quantification of foci 
was carried out using ImageJ.  
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4.1 Discussion 
Since the identification of FA as an inherited genomic instability disease, the 
molecular machinery of the FA pathway has been studied intensively in the context of 
DNA ICL repair. Accumulating evidence strongly supports a model where the FA 
proteins act in a linear hierarchy during ICL repair. In this model, monoubiquitination of 
the central FANCD2/FANCI heterodimer by the FA core complex is a key step that is 
indispensable for the subsequent recruitment of downstream FA pathway members, such 
as BRCA2, FANCJ and other HR factors to promote nucleolytic ICL removal and repair 
of the ensuing DNA DSB (Ceccaldi et al., 2016a; Walden and Deans, 2014; Wang, 
2007). While this model is widely accepted in the FA research field, it does not account 
for the fact that FA patients do phenotypically differ from one another. Perhaps most 
strikingly, patients with mutations in proteins that act downstream of the FA core 
complex exhibit much more severe phenotypes, such as more frequent congenital 
anomalies and early manifestations of the hematological and neoplastic defects (Bakker 
et al., 2013b; Kalb et al., 2007; Litman et al., 2005). This in turn suggests that the FA 
pathway members from the central or downstream tiers must have additional cellular 
functions beyond DNA ICL repair.  
Indeed, there has been a surge in the identification of alternative roles of the FA 
pathway members (Ceccaldi et al., 2016a). Several additional roles were assigned to 
FANCD2, such as 1) a transcriptional regulatory role to promote gene expression of the 
TAp63 tumor suppressor; 2) a role in resolving DNA–RNA hybrids arising from 
collisions of the transcription and replication machineries (García-Rubio et al., 2015);  3) 
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a role in the so-called alternative NHEJ pathway (a DSB repair pathway that utilizes 
microhomology-mediated end joining (Kais et al., 2016)) and  4) a role in promoting the 
initiation of normal DNA replication in S-phase (Chaudhury et al., 2013; Song et al., 
2010). Additionally, the downstream members of the FA pathway such as FANCJ and 
BRCA2 have been shown to play an important role in promoting DNA DSB repair during 
S-phase,  using the HR pathway (Costanzo, 2011; Levitus et al., 2005; Zhang et al., 2009) 
Previous work from our laboratory provided additional insights into S-phase 
specific roles of FANCD2 and FANCI. Using the Xenopus egg extract system, we 
showed that FANCD2 and FANCI dissociate during the replication stress response in S-
phase. Moreover, we showed that chromatin recruitment and monoubiquitination of 
FANCD2 and FANCI occurs in a consecutive, not simultaneous, manner (Sareen et al., 
2012). Subsequently, we demonstrated that FANCD2- but not FANCI - has important 
functions at replication forks that are stalled in the presence of the replication inhibitors 
APH or HU. We showed that FANCD2 assembles the BLM helicase complex at stalled 
replication forks independently of FANCI (Chaudhury et al., 2013). Moreover, we 
demonstrated that FANCD2 promotes replication fork restart and suppresses the firing of 
new replication origins in concert with the BLM helicase complex, CtIP and FAN1 
(Chaudhury et al., 2013, 2014; Yeo et al., 2014). This role for FANCD2 at replication 
forks is likely to be more fundamental than ICL repair for the cellular survival and the 
prevention of carcinogenic genome alterations. Spontaneous stalling of the replication 
machinery can occur during every S-phase at numerous natural impediments such as 
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seconday DNA structures, late replicating heterochromatic zones, or DNA-bound protein 
complexes such as the transcription machinery (Branzei and Foiani, 2010).  
The work described in this thesis builds on these newly identified roles of 
FANCD2 at stalled replication forks and attempts to answer two major outstanding 
questions: 1) Does FANCD2 promote the restart of stalled replication forks 
independently of the other FA pathway members? 2) What is the underlying molecular 
mechanism that allows FANCD2 to support the restart of these stalled forks?  
Through the studies described in Chapter 2, I sought to answer whether other FA 
pathway members cooperate with FANCD2 to support the replication fork restart 
process. In complete agreement with the idea that the central and downstream FA 
pathway members do have roles that are not shared by the FA core complex, I 
demonstrated that FANCD2 is recruited to APH-stalled replication forks to promote fork 
restart independently of the FA core complex. Since FANCD2 relies strictly on the FA 
core complex for its own monoubiquitination, my findings also demonstrated – for the 
first time – that the nonubiquitinated FANCD2 isoform has a crucial role during the S-
phase of the cell cycle. Moreover, this nonubiquitinated FANCD2 isoform acts in concert 
with at least two downstream FA proteins, BRCA2 and FANCJ, to promote fork restart, 
reemphasizing that FANCD2 and its downstream targets participate in crucial cellular 
pathways that act independently of the FA core complex. Collectively, my results support 
a novel, non-linear FA pathway model during the cellular replication stress response. 
In further support of my findings, a follow up study showed that FANCD2 
maintains the stability of common fragile sites (genomic regions that are prone to break 
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under replication stress) independently of the FA core complex proteins and of the 
FANCD2 monoubiquitination event, but in concert with BRCA2, (Madireddy et al., 
2016). The importance of the nonubiquitinated FANCD2 isoform during the replication 
stress response is also supported by a recent finding that the nonubiquitinated FANCD2 
protein is crucial  to support cellular resistance to HU-mediated replication stress (Chen 
et al., 2016).    
It should be pointed out that two other studies seemingly contradict my model that 
FANCD2 and BRCA2 cooperate to promote fork restart (Kais et al., 2016; Michl et al., 
2016).  In contrast to my observations, these studies found that FANCD2 and BRCA2 
can contribute independently to replication fork recovery. Some of these discrepancies 
could be due to the difference in the cell lines used in these studies; for example one 
study analyzed FANCD2 and BRCA2 protein behavior in a lung carcinoma (H2199) cell 
line instead of using human FA patient-derived cells. Moreover, both studies utilized a 
different strategy to analyze replication fork recovery: the authors quantified replication 
fork progression following replication fork stalling, thus analyzing fork speed after 
restart. In contrast, my study directly quantified the actual number of fork restart events, 
raising the possibility that fork restart and fork speed following restart are differently 
regulated by FANCD2 and BRCA2.  
Following the identification of nonubiquitinated FANCD2 as a key factor to 
mediate the restart of APH- or HU-stalled replication forks, I attempted to investigate the 
actual mechanism of FANCD2-mediated fork restart in Chapter 3. I determined that 
FANCD2 interacts and cooperates with the histone H3.3 chaperone complex 
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ATRX/DAXX, to mediate the restart of HU-stalled replication forks. Intriguingly, my 
findings support a model where histone chaperone activity of both the ATRX/DAXX 
complex and FANCD2 are required to promote fork recovery, suggesting that the 
deposition of one (or more) histone variants in the vicinity of stalled replication forks is a 
crucial step towards fork recovery. Moreover, my findings support a model where 
ATRX/DAXX, FANCD2, and several other HR factors cooperate as part of a larger 
protein complex to ultimately mediate HR-dependent mechanisms of replication fork 
restart and repair.  
 While my findings in these chapters identify novel roles for the central and 
downstream tiers of the FA pathway at stalled replication forks, it raises several new 
questions regarding the molecular basis of these newfound roles. In the remainder of this 
chapter, I address outstanding questions resulting from this work that should provide 
interesting avenues for future research. 
4.2 Future Directions 
4.2.1 How do the remaining downstream FA pathway members fit into my proposed 
FANCD2/FANCJ/BRCA2-dependent replication fork restart model? 
Accumulating evidence indicates that the restart of APH or HU stalled replication 
forks relies on HR mechanisms that may involve D-loop formation and Holliday junction 
dissolution (Petermann and Helleday, 2010).  Importantly, seven of the ten currently 
known downstream FA pathway members (Tier III, Fig. 1.3) are known to be crucial for 
HR. Studies from other laboratories as well as from our own have already implicated six 
of them, namely BRCA1, BRCA2, FANCJ, RAD51, RAD51C and XRCC2, in the restart 
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of HU- or APH-stalled replication forks  (Petermann et al., 2010; Raghunandan et al., 
2015a; Somyajit et al., 2015; Yeo et al., 2014). The seventh downstream HR factor, 
FANCN, is a known interactor of BRCA1 and BRCA2 (Zhang et al., 2009), and thus 
highly likely to be required for fork recovery as well. In fact, we have unpublished 
preliminary results indicating that FANCN acts in concert with the other downstream FA 
HR proteins to promote the recovery of replication stalled forks.  
What about the three other downstream FA pathway proteins, namely 
FANCP/SLX4, its binding partner and endonuclease FANCQ/XPF-ERCC1 and the TLS 
DNA polymerase  subunit, FANCV/Rev7? During HR-dependent fork restart, I envision 
that the FA pathway endonuclease could be involved in the resection of the dsDNA 
strand at a reversed fork (“Chicken Foot”) to generate single stranded 3’ overhangs that 
facilitate RAD51 mediated strand invasion (D-loop) and subsequent fork regeneration 
and restart. I hypothesize that SLX4 and FANCQ/XPF/ERCC1 may behave similar to the 
FAN1 endonuclease that – albeit not an FA protein itself – promotes replication fork 
restart in a FANCD2-dependent manner (Chaudhury et al., 2014). It seems less likely that 
fork recovery after APH- or HU-mediated fork stalling should require a translesion DNA 
polymerase such as DNA pol , however additional studies are needed to answer this 
question. 
Perhaps the most interesting question in the context of FA pathway-mediated fork 
recovery is whether the FANCD2 heterodimerization partner, FANCI, is required for 
replication fork restart. In the canonical FA pathway model, the ID2 heterodimer acts as a 
functional entity that must be monoubiquitinated to promote ICL repair. However, data 
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from our laboratory indicated that FANCD2 and FANCI actually dissociate in response 
to replication stress, and bind chromatin separately, in a step-wise manner (Sareen et al., 
2012). Moreover, we previously showed that FANCD2 assembles the BLM helicase fork 
restart complex independently of FANCI and therefore independently of the FANCI-
dependent FANCD2 monoubiquitination (Chaudhury et al., 2013). These findings 
suggest that FANCI may in fact be dispensable for fork restart. To address this question, 
we recently generated, in addition to the already available FANCD2-/- cells, FANCI-/- and 
ID2 double knockout (DKO) cells in the isogenic HCT116 cell background. We are 
currently using our standard DNA fiber assay to dissect the contributions of FANCD2 
and FANCI to HR-mediated replication fork recovery.  
4.2.2 How does FANCD2 monoubiquitination regulate its functions at a stalled 
replication fork? 
Based on my findings and findings from other laboratories, it is now clear that at 
both the FA core complex and FANCD2 are required to protect the nascent DNA strands 
at stalled replication forks from nucleolytic degradation. In contrast, FANCD2 – but not 
the FA core complex - is required to promote fork restart (Chaudhury et al., 2013; 
Raghunandan et al., 2015; Schlacher et al., 2012). This immediately suggests a strict 
separation of function between the monoubiquitinated and the nonubiquitinated FANCD2 
isoforms: monoubiqitinated FANCD2 acts to protect nascent DNA at the stalled fork, 
whereas nonubiquitinated FANCD2 functions to promote fork restart. Interestingly, two 
recent studies showed that following DNA ICL induction in human cells, the non-
ubiquitinated FANCD2 protein is recruited to the chromatin prior to being 
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monoubiquitinated by the FA core complex. These new findings hint that the 
nonubiquitinated and monoubiquitinated FANCD2 isoforms may fulfill distinct roles 
even during DNA ICL repair (Liang et al., 2016; van Twest et al., 2017).  
How can one envision this separation of function at a molecular level? Firstly, 
nonubiquitinated, but not monoubiquitinated, FANCD2 may serve as a docking platform 
to recruit other replication restart proteins. This idea is strongly supported by our 
previous findings that fork restart factors such as BLM or CtIP interact preferentially 
with the nonubiquitinated FANCD2 isoform even after FANCD2Ub induction with APH 
or HU (Chaudhury et al., 2013; Yeo et al., 2014). Moreover, the FANCD2-FAN1 protein 
interaction that occurs in an APH- or HU- stimulated manner and is crucial for replication 
fork recovery, occurs independently of the FA core complex and thus independently of 
FANCD2Ub formation. Somewhat provocatively, these findings actually suggest that 
FANCD2Ub formation may actively interfere with FANCD2’s ability to serve as a 
platform for the replication fork restart machinery.  
To test this idea, we plan to perform in vitro interaction studies using recombinant 
FANCD2, BLM, CtIP and FAN1 proteins. Since the human recombinant FANCD2 
protein is quite unstable in vitro (our observation and personal communication with Dr. 
Andrew Deans, St Vincent's Institute of Medical Research, Australia), we plan to perform 
these experiments with the Xenopus homologs, xFANCD2, xBLM, xCtIP and xFAN1. 
Specific antibodies are at hand for all four Xenopus proteins (Chaudhury et al., 2013; 
Klein Douwel et al., 2014; Peterson et al., 2013). To achieve xFANCD2 
monoubiquitination in vitro, we will incubate recombinant xFANCD2 with the 
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appropriate recombinant E2 and E3 ubiquitin ligases, UBE2T and FANCL, respectively 
(Alpi et al., 2008), followed by interaction studies with one of the three predicted 
interaction partners. Additionally, we are planning to use eight already generated 
truncation mutants of xFANCD2 to map the interaction surfaces that FANCD2 utilizes to 
make physical contact with BLM, CtIP or FAN1. Currently, no protein interaction sites 
(other than those with FANCI) have been mapped onto the FANCD2 protein. Ultimately, 
selective interaction-deficient human FANCD2 mutants expressed in our D2-/- cells 
would provide us with a powerful model to dissect the importance of individual 
FANCD2 protein interactions during the replication stress response.  
If our model holds true, the monoubiqitinated FANCD2 isoform should not 
interact with fork restart factors, but should somehow protect the nascent DNA strands 
from nucleolytic attack by nucleases such as MRE11 or DNA2, as previously reported 
(Schlacher et al., 2012; Thangavel et al., 2015; Ying et al., 2012). How can FANCD2 
perform this protective role? FANCD2Ub appears to have a higher affinity to chromatin 
than the nonubiquitinated FANCD2, hinting that FANCD2Ub may bind more tightly to 
DNA at stalled replication forks, thus, protecting the nascent DNA ends. Intriguingly, a 
recent DNA ICL repair study in Xenopus egg extracts found that approximately 50 
FANCD2Ub molecules bound to each ICL (Douwel et al., 2014), indicating that 
FANCD2Ub tends to bind to a target region on DNA and then spread to the surrounding 
DNA. If similar actions occurred at stalled replication forks, one could envision that 
FANCD2Ub “filaments” spread out behind the stalled replication fork to stabilize the 
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nascent DNA, while nonubiquitinated FANCD2 molecule(s) engages in replication fork 
restart.  
4.2.3 What is the underlying molecular mechanism of FANCD2 and ATRX/DAXX-
dependent, histone H3 variant-mediated replication fork restart? 
To answer this question, I propose the following step-wise strategy:  
a) Does FANCD2 share the same histone H3.3 variant specificity as the ATRX/DAXX 
complex? 
FANCD2 has been previously identified to possess histone H3 chaperone activity 
using in vitro nucleosome assembly assays. However, the authors did not clarify which of 
the common histone H3 variants (3.1, 3.2 or 3.3) were actually analyzed in their in vitro 
or in vivo analyses (Sato et al., 2012, 2014). In chapter 3, I showed that replication fork 
restart relies on a functional interaction between FANCD2 and the ATRX/DAXX 
complex that is known to selectively deposit the H.3.3 variant onto chromatin (Drané et 
al., 2010; Goldberg et al., 2010; Lewis et al., 2010). This suggests that FANCD2’s own 
histone chaperone activity may be targeted (directly or indirectly via ATRX/DAXX) 
towards the H3.3 variant. To investigate this, I plan to use several approaches: (1) Test if 
FANCD2 participates specifically in nuclear histone H3.3, but not histone H3.1 or H3.2 
protein complexes in vivo. To this end, I am currently generating cell lines that stably 
express a combination of 3xFLAG-FANCD2 with EGFP-H3.1, EGFP-H3.2 or EGFP-
H3.3 (the EGFP-histone plasmids are a kind gift from Dr. Luis M. Schang, University of 
Alberta (Conn et al., 2013)). Following stable expression, we will isolate H3.1, H3.2 or 
H3.3-containing protein complexes using tandem-affinity purification from soluble, 
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chromatin free nuclear extracts using protocols described previously for the identification 
of DAXX-H3.3 protein complex (Lewis et al., 2010). (2) Test if FANCD2 interacts 
selectively with histone H3.3 in vitro. We will perform in vitro immunoprecipitation 
assays using recombinant xFANCD2 and recombinant histone H3.1, H3.2 or H3.3 (the 
H3.1, H3.2 and H3.3 amino acid sequences are identical between the human and Xenopus 
homologs) purified from SF9 insect cells, as previously described (Chaudhury et al., 
2013; Sareen et al., 2012). In this context, we also need to consider that FANCD2 may 
only interact with a post translationally modified form of histone H3.3. All histone 
variants can be targeted by a multitude of posttranslational modifications (PTMs) in vivo 
(Hunt et al., 2013; Szenker et al., 2011). Should FANCD2 only bind to post 
translationally modified H3.3, we will not pick up on this interaction in an assay that uses 
non-modified histone H3 variants. As an alternative approach, we plan to screen for 
binding of recombinant xFANCD2 against a commercially available histone peptide 
array that is composed of H3 variant peptides that carry distinct PTMs including 
acetylation, mono-, di- or tri-methylation, phosphorylation etc. (Moore et al., 2013).  
Additionally, there is no direct evidence of any histone H3 variant deposition 
specifically at or behind the stalled forks. To test for histone deposition at or in the 
vicinity of stalled replication forks, we will perform the iPOND assay (isolate proteins on 
nascent DNA (Sirbu et al., 2012)). The iPOND enables the purification of proteins bound 
to the nascent synthesized DNA and obtain a high-resolution spatiotemporal analysis of 
proteins at replication forks or on chromatin following DNA replication fork stalling. 
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b) Is histone H3.3 deposition required to promote fork restart? 
My results described in Chapter 3 demonstrate that the ATRX/DAXX complex 
promotes replication fork restart, indirectly suggesting that it is the ATRX/DAXX-
mediated H3.3 deposition at stalled forks that is crucial for fork restart. However, it is 
possible that ATRX and DAXX promote restart independently of their function as 
histone H3.3 chaperone. To test this, we recently received a H3.3B knock-out MEF cell 
line (a generous gift from Dr. Paul Knoepfler, University of California, Davis (Bush et 
al., 2013)). This cell line exhibits very low H3.3 protein levels that stem from residual 
expression from the H3.3A gene locus. We will use the DNA fiber assay in WT and 
H3.3B knock-out MEFs to analyze replication fork restart efficiencies following HU 
treatment. Simultaneously, we will perform the same DNA fiber assays in human cells 
treated with control siRNA or H3.3 siRNA. Our idea that H3.3 may be required to 
promote the restart of HU-stalled replication forks, is supported by previous studies that 
report a crucial role for H3.3 to promote the progression of the replication machinery in 
the presence of UV light-induced DNA damage in vertebrate cells (Adam et al., 2013; 
Frey et al., 2014). 
4.2.4 Does FANCD2 share ATRX’s role in telomere maintenance? 
ATRX has been closely associated with the maintenance of genomic integrity at 
telomeric DNA (Koschmann et al., 2016; Wang et al., 2016; Wong et al., 2010). 
Telomeres are the specialized nucleoprotein structures (DNA coated with “shelterin” 
proteins such as TRF1) that protect the ends of the chromosomes from being recognized 
as a DNA DSB (Doksani and de Lange, 2014; Sfeir et al., 2009). Since the telomeric 
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DNA consists of G-rich repeat sequences (TTAGGG), it has a high propensity to form 
secondary DNA structures called G4 quadruplexes. G4 structures are natural 
impediments for the DNA replication machinery (Bochman et al., 2012). ATRX binds 
G4 quadruplexes in vitro and  associates with the G-rich telomeric and subtelomeric 
repetitive DNA in vivo (Law et al., 2010). The ATRX/DAXX complex promotes 
incorporation of the histone variant H3.3 at telomeric repeats, which was shown to 
counteract replication fork stalling events. It has been proposed that ATRX/DAXX 
mediated H3.3 deposition and H3.3K9me3 formation at telomeric regions likely 
increased telomere chromatinization, which in turn should limit the formation of G4 
structures (Clynes et al., 2015; Goldberg et al., 2010; Lewis et al., 2010; Lovejoy et al., 
2012). Since FANCD2 and ATRX have shared roles at APH- or HU-stalled replication 
forks, it seems plausible to hypothesize that FANCD2 may shares ATRX’s role in 
promoting H3.3-dependent chromatinization at the repetitive G4-prone DNA sequences 
to support telomere maintenance. In agreement with possible protective roles of 
FANCD2 at telomeres, previous reports showed that cells from FA-D2 patients and 
patients of other FA complementation groups (such as BRCA2) exhibit shorter telomeres 
with an average length in the lower quarter of the “normal” range as well as telomere 
loss/breakage in peripheral leukocytes (Adelfalk et al., 2001; Alter et al., 2015; Joksic et 
al., 2012).  
In ATRX null cells, a reduction in H3.3 density at the telomeres suggests 
decreased chromatinization (Clynes et al., 2015). If FANCD2’s contribution to telomere 
integrity maintenance is via its role as a histone chaperone, we would expect to see 
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reduced H3.3 densities at the telomeric region in FANCD2-deficient cells as well. This 
can be tested by performing a chromatin immunoprecipitation (ChIP) assay for H3.3 in 
our WT and D2-/- cells, to probe for enrichment of telomeric DNA using slot blotting 
techniques (Clynes et al., 2015). Additionally, a reduction in H3.3 density at telomeres is 
typically accompanied with an increase in G4 quadraplex formation observed in ATRX 
deficient cells (Wang et al., 2016). Using commercially available G4 antibodies in a co-
staining experiment using a Telomere specific- Fluorescence in situ hybridization (T-
FISH) analysis, we can examine 1) if more G4 structures accumulate in the D2-/- cells 
compared to WT cells and 2) if the accumulating G4 structures in D2-/- cells occur 
predominantly at telomere structures.  
The idea that FANCD2 may cooperate with ATRX/DAXX to support DNA 
replication through G4 structure-prone regions at telomeres is additionally supported by 
recent findings that the BLM helicase, a known functional interactor of FANCD2 during 
global replication fork restart (Chaudhury et al., 2013; Davies et al., 2007) is crucial in 
facilitating telomere DNA replication (Drosopoulos et al., 2015). To examine if BLM, 
FANCD2 and ATRX/DAXX function in concert to promote telomere replication, we 
plan use the telomere SMARD (Single molecule analysis of replicated DNA) assay (Sfeir 
et al., 2009). Telomere-SMARD is a modified DNA fiber assay which can further 
specifically enrich for telomeric DNA. This telomeric DNA enrichment step enables 
analyzing replication events exclusively at telomeric DNA sequences. Should I observe 
that the BLM helicase, FANCD2 and ATRX/DAXX are required to support timely 
replication of telomeric DNA, it would be quite interesting to test if other known 
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FANCD2 interactors, such as MRE11, CtIP, FAN1 and additional downstream FA 
pathway proteins share this new role of FANCD2 as well.  
4.2.5 Does FANCD2’s predicted role in telomere maintenance in normal cells change 
in ALT cancers? 
ATRX’s role in maintaining telomeric integrity becomes particularly evident 
upon the examination of cancer cells lacking ATRX. Approximately 5-15% of cancers 
utilize an alternative, HR based telomere maintenance mechanism named ALT 
(Alternative Lengthening of Telomeres). ALT cells lack any detectable telomerase 
activity and show a characteristic heterogeneous pattern of telomere length (ranging from 
1 kb to 20 kb). A previous study that used uniquely tagged telomeres in an ALT cell line 
showed that the tag is dispersed to the telomeric ends of different chromosomes, strongly 
suggesting that ALT cells use HR mechanisms to maintain their telomeres. However, the 
molecular details of ALT are yet to be elucidated (Pickett and Reddel, 2015; Zhong et al., 
2007). 
Strikingly, 90% of all ALT cancers lack the expression of ATRX, DAXX or H3.3 
(Pickett and Reddel, 2015). In these ALT cancer cells, FANCD2 and other HR proteins 
such as BLM and MRE11 are known to localize excessively to the telomeres, visible as 
telomere associated foci (Clynes et al., 2015; Fan et al., 2009; Root et al., 2016). Within 
these foci, FANCD2 and MRE11 are predicted to promote ALT mechanisms and support 
telomere length heterogeneity (Fan et al., 2009; Zhong et al., 2007).  This peculiar 
observation suggests that ATRX/DAXX may in fact prevent an inappropriate over-
accumulation of HR factors at the telomeres in normal cells. In fact, it was recently 
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shown that re-expression of ATRX in an ALT cancer cell line, U2OS, annihilated 
MRE11 telomere foci formation. (Clynes et al., 2015). Should ATRX re-expression also 
block telomere formation of FANCD2 and other HR factors in ALT cells, one would 
predict that ATRX negatively regulates the recruitment of FANCD2 and other HR 
proteins to chromatin, thus repressing HR. In complete contrast, my findings in Chapter 3 
suggest that ATRX and FANCD2 cooperate to recruit HR factors, such as CtIP, to stalled 
replication forks and to support HR mechanisms towards fork restart. Additionally, the 
possibility that FANCD2 and ATRX/DAXX may both support DNA replication through 
G4 structure-prone regions at telomeres via their histone H3 chaperone activities (Section 
4.4) provides further support that FANCD2and ATRX/DAXX complex work as a team at 
normal telomeres.  
One potentially unifying model for these seemingly opposing findings would 
predict that ATRX and FANCD2 cooperate at stalled replication forks – including those 
that occur within the telomeric regions –  to promote HR-dependent restart mechanisms. 
At the same time, ATRX may very strictly regulate how many FANCD2 molecules are 
permitted to access the telomeric DNA, perhaps via controlling additional FANCD2 
protein interactions, to prevent over-accumulation of FANCD2 and other HR factors. 
To test if ATRX does in fact prevent overloading of FANCD2 molecules at 
telomeres, we plan to perform a T-FISH analysis of our non-ALT ATRX-/o cells and their 
complemented counterpart, ATRX-/o+ATRX.  
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Simulataneously, we plan to test if the mode of interaction between ATRX and 
FANCD2 occurs differently at the telomeres compared to the rest of the genome. To this 
end, we will employ a recently developed DR-GFP assay using Cas9 nucleases to create 
site specific DSBs (Vriend et al., 2014). We will use our WT, ATRX-/o, D2-/- and D2AX-/- 
cells and engineer into each cell line the DR-GFP cassette either within a 
telomeric/subtelomeric DNA sequence or at a non-telomeric genomic DNA sequence. 
Subsequently, Cas9 transfection in the presence of a sceGFP guide RNA will induce a 
DNA DSB within the GFP gene present in the distinct genomic contexts (Vriend et al., 
2014).  The percentage of HR-proficient, GFP-positive cells can then be determined by 
flow cytometric analysis. Using this assay, we will determine the contributions of ATRX 
and FANCD2 to HR mediated-DNA DSB repair at the non-telomeric regions versus the 
telomeric ones. If ATRX does indeed prevent FANCD2-mediated HR events at 
telomeres, we expect to observe an increase in HR-mediated telomeric GFP repair in 
ATRX-/o cells compared to the WT, D2-/- and D2AX-/- cells.  
In conclusion, the studies presented in this dissertation have greatly enhanced our 
understanding of the molecular FA pathway. This work demonstrates novel and non-
canonical roles for the FA pathway proteins at stalled replication forks. Moreover, it sets 
a strong precedent for examining the role of individual FA proteins as they may have 
additional, not yet recognized functions independently of their canonical DNA ICL repair 
roles. In my studies, I show convincing evidence for a functional relationship of 
FANCD2 with the histone chaperone, ATRX/DAXX. These findings argue for putative 
roles of at least one FA protein in regulating chromatin dynamics to promote error-free 
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and timely DNA replication. Importantly, this novel view of the FA pathway has 
immense therapeutic potential for the development of novel future treatment strategies 
for FA patients and FA-type cancers in the normal population. Histone methylation for 
example is a therapeutically actionable realm, with several chemicals that activate or 
inhibit histone modifiers currently undergoing phase II clinical trials. Beyond the realm 
of FA mutated cancers, additional studies that further our understanding of ALT cancers 
and the role of FANCD2 in this cancer subtype, will enable the development of 
alternative cancer therapies, and ultimately strengthen our fight against cancer. 
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